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ABSTRACT 
KINETIC AND DYNAMIC INSIGHTS INTO THE SUBSTRATE 
INTERACTIONS AND CATALYSIS OF FACTOR INHIBITING HIF-1 (FIH-1) 
CRISTINA B. MARTIN, B.S., UNIVERSITY OF THE PHILIPPINES 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Michael J. Knapp 
 
Factor inhibiting HIF-1 (FIH-1) modulates the master regulator of hypoxia 
sensing, hypoxia inducible factor-1 (HIF-1), by transcriptional repression making it an 
attractive potential target for treatment of hypoxia-related diseases. Given that similar 
enzymes are present within the cell and that they have other important physiological 
roles, defining the therapeutic window by which it can be selectively targeted becomes an 
issue. Consequently, it’s necessary to have a deeper understanding of the substrate 
interactions in FIH-1 that contributes to catalysis as this is one avenue that can be 
explored for future therapeutic investigations. The overall goal of this dissertation is to 
gain kinetic and dynamic insights into the substrate interactions and catalysis of FIH-1 
that can be used in the future to improve its selective inhibition over the related prolyl 
hydroxylase domain enzymes (PHDs). The term dynamic here loosely refers to the 
conformational flexibility of the enzyme.  
An initial screen of inhibitor compounds that mimic the cosubtrate, αKG, was 
performed with the goal of teasing out compound properties that might be useful for 
selectively inhibiting FIH-1 over the PHD isoform studied in the lab, PHD2, and vice 
versa. Results from steady state kinetic assays supported by EPR spectroscopy showed 
	   vii	  
that planar compounds are more effective at inhibiting PHD2 than FIH-1. One or two 
compounds belonging to the pyrone/pyridinone framework may prove promising for 
future development of selective FIH-1 inhibitors. 
The succeeding studies were done in an effort to uncover unique substrate 
interactions of FIH-1 that might provide further useful information for future selective 
inhibition studies. Firstly, the effect of α-ketoglutarate (αKG) binding on the primary 
substrate interactions of FIH-1 was tested. Initial observations in the lab, as well as 
previous reports on the effect of αKG binding on the stability of similar enzymes, led us 
to hypothesize that αKG binding induces conformational changes in FIH-1 which are in 
turn required for the optimal binding of the primary substrate HIF-1α/C-terminal 
transactivation domain (CTAD). To address this, fluorescence and thermal shift 
experiments in addition to global hydrogen/deuterium exchange and limited proteolysis 
coupled to mass spectrometry were performed. The data strongly implies a more tightly 
folded structure of FIH-1 when bound to αKG. This is corroborated by the observations 
that for the ternary enzyme-metal-αKG complex, (1) it is more thermally stable, (2) it is 
less prone to solvent and protease attack, and (3) it apparently exhibits higher affinity for 
the substrate HIF-1α/CTAD compared to apo or metal-bound form of the enzyme. The 
data allowed for the conception of a model in which at least two conformational states of 
the enzyme exist in equilibrium depending on the presence of αKG. The more rigid 
structure likely primes the enzyme for optimal substrate binding via pre-formation of the 
binding site, the configuration of which is tightly coupled to efficient turnover.  
Lastly, the role of a protein loop on the substrate interactions and catalysis of 
FIH-1 was tested. Based on (1) a previous computational study indicating that a loop 
	   viii	  
containing residues 100-110 of FIH-1 (which we called the 100s loop) becomes less 
flexible in the presence of substrate and (2) an analysis of the crystal structure revealing 
the FIH-1 loop residue Tyr102 stacked on top of the substrate target residue Asn803, we 
hypothesized that the 100s loop via Tyr102 is involved in substrate binding and turnover. 
The results from steady state kinetic assays combined with UV-vis and EPR spectroscopy 
as well as succinate quantitation experiments performed on loop mutants indicates that 
(1) the contribution of the loop residue Tyr102 to substrate binding is mainly through 
steric interaction and that (2) this steric interaction ensures the tight coupling of substrate 
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CHAPTER 1 




The survival of metazoans is crucially dependent on oxygen levels. Oxygen is a 
critical part of the aerobic energy production process of the cell where it serves as the 
terminal electron acceptor. During this process called oxidative phosphorylation, energy 
from organic substrates is chemically transformed into ATP, which is required by the cell 
to maintain viability. ATP is also produced anaerobically via glycolysis but, unless there 
is endless supply of available glucose and constitutively enhanced glycolytic enzyme 
activities, this pathway cannot sufficiently meet the energy demands of a multicellular 
organism whereas aerobic respiration can. Hence, physiological mechanisms have 
evolved early on to efficiently maintain oxygen homeostasis within the organism at the 
tissue and cellular level.[1,2] 
Decreased oxygen availability leads to the condition known as hypoxia, which can be 
disastrous to normal cells even for transient periods of time. Hypoxia occurs not only 
during disease states like ischemic disorders and cancer but also during normal 
embryonic development[3,4]. Thus, metazoans evolved an elaborate network that is 
critically sensitive to low partial pressures of oxygen to ensure the critical adaptation and 
response to such conditions. Hypoxia response in humans can be categorized as acute or 
chronic depending on the severity and timeframe of oxygen deprivation. The acute 
response occurs in the seconds to minutes time scale. The response largely involves 
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excitation of ion channels that result in rapid cardiorespiratory changes such as 
hyperventilation and enhanced cardiac output at the tissue level; and metabolic switch 
from aerobic to anaerobic respiration at the cellular level. The chronic response, on the 
other hand, occurs in the hours to days time scale and mainly involves induction of 
oxygen-dependent gene expression with the overall effect of enhancing the O2-carrying 
capacity of the blood and decreasing cellular O2 utilization.  In addition to mediating the 
aforementioned physiological responses triggered at the onset of hypoxia, the chronic 
response also results in activation of angiogenesis and erythropoiesis among many 
others.[2,4] Hypoxia sensing regulated by the transcription factor HIF generally falls under 
the chronic response category whereby prolonged hypoxia allows for the stabilization and 
accumulation of HIF that results to maximal trans-activational effect[98,99].  
 
1.2 Key Regulators of Hypoxia Sensing 
1.2.1 Hypoxia-Inducible Factor-1 (HIF-1) 
The hypoxia-inducible factors (HIFs) mediate the crucial ability of metazoans to 
respond to changes in oxygen availability via activation of genes that are essential for cell 
survival under hypoxia[5,7,26-33]. Of the three members of this family, HIF-1 largely takes 
the role of the master regulator of hypoxia sensing in humans primarily because of its 
widespread tissue expression[104,105]. HIF-1 is an α/β heterodimeric protein belonging to 
the basic helix-loop-helix (bHLH)/Per-ARNT-Sim (PAS) superfamily of transcription 
factors (Figure 1.1A)[6]. This contiguous structural motif allows HIF-1 to bind to the 
major groove of DNA, specifically to the canonical 5’-(G/A)CGTG-3’ site within 
hypoxia responsive elements (HREs) in the promoter regions of target genes[7-11,102]. The 
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bHLH/PAS motif also allows for the heterodimerization of the 120 kDa oxygen-regulated 
HIF-1α subunit with the constitutively expressed 91-94 kDa HIF-1β also known as aryl 
hydrocarbon acceptor nuclear translocator (ARNT)[6,12,13]. Formation of the HIF-1 
heterodimer is critically required for DNA binding while recruitment of the co-activators 
like p300/CBP, SRC-1 and TIF2 are needed for gene trans-activation[14,15,21,22,115]. The 
co-activators in general serve as molecular platforms for the assembly of the 
transcriptional machinery[118,119].  The HIF-1α subunit has two trans-activation domains 
(TADs), one in the N-terminus called NTAD (residues 531-575) and another in the C-
terminus called CTAD (residues 786-826) (Figure 1.1A)[101,103]. Unlike HIF-1α, which is 
ubiquitously expressed[104,105], the HIF-2α and HIF-3α subunits are selectively expressed 
and localized in certain tissues like the lungs and blood vessels[16-18,108]. Although the 
exact reason for the existence of the three isoforms is yet to be elucidated, it has been 
suggested that each HIF protein plays a complementary rather than a redundant role in 
hypoxia sensing[18,100]. 
HIF-1 is tightly regulated in the cell by two oxygen-dependent hydroxylation 
mechanisms illustrated in Figure 1.1B: (i) protein degradation and (ii) transcriptional 
repression. The first mechanism is mediated by the prolyl hydroxylase domain (PHD) 
enzymes, which under normoxic conditions hydroxylate conserved proline residues of the 
α subunit. This targets HIF-1α for proteasomal degradation, hence, the protein has a 
short half life of about 5 mins.[19,20,51] The second hydroxylation-based regulatory 
mechanism is mediated by factor inhibiting HIF-1 (FIH-1), which is the protein under 
study in this dissertation. Under normoxic conditions, FIH-1 catalyzes the hydroxylation 
of a highly conserved asparagine residue in the C-terminal transactivation domain or  
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Figure 1.1 (A) Simplified diagram illustrating the domains of the HIF-1 subunits. Also 
shown are the proline residues in the N-terminal trans-activation domain of the α subunit 
hydroxylated by PHDs and the asparagine residue in the C-terminal trans-activation 
domain hydroxylated by FIH-1. (B) Schematic diagram of the oxygen-dependent 
regulation of HIF-1α by PHDs and FIH-1. 
 
 
CTAD of the α subunit. This modification hinders the binding of the co-activator 
p300/CBP, which in turn represses the transcriptional activity of HIF-1[21-24]. The fact 
that both the PHDs and FIH-1 regulate HIF-1 activity by O2-dependent mechanisms 
made these hydroxylases primary cellular oxygen sensors. 
Under hypoxic conditions, HIF hydroxylase activity is significantly reduced and 
so the HIF-1α subunit escapes the O2-dependent posttranslational modifications. HIF-1α 
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accumulates and translocates from the cytoplasm to the nucleus where the HIF-1 subunits 
dimerize and, along with the co-activators like p300/CBP, are able to activate the 
transcription of about a thousand genes to date as surveyed using chromatin 
immunoprecipitation sequencing (Figure 1.1B)[109,110]. Protein products of these activated 
genes are involved in glucose metabolism[5,26-28,111], angiogenesis[29,30], erythropoiesis[7], 
cell survival, and iron uptake[31-33] among many others. These processes have been very 
much implicated in the pathophysiology of disease states such as cancer[106,107], 
myocardial and cerebral ischemia[34], pulmonary hypertension and anemia[35,36]. It is not 
surprising then that HIF-1 and its molecular regulators, PHDs and FIH-1, are attractive 
potential drug targets for these diseases. In fact, just very recently, several drug 
companies like Fibrogen and Bayer have already began developing inhibitor compounds 
mostly targeting the PHDs for the treatment of anemia, wound healing, heart disease and 
pulmonary hypertension[84,85]. Though many of the compounds tested seem very 
promising, only one or two have so far entered phase III clinical trials. A lot more of the 
compounds turned out to be failures. It becomes apparent that at this stage, the ability to 
manipulate the HIF hydroxylases selectively for productive therapeutic purposes still 
necessitates a more profound understanding of their structures and functions. 
Consequently, any information that will provide insight into the mechanism of the HIF 
hydroxylases, FIH-1 being the focus in this dissertation, (1) may contribute to the current 
understanding of how the HIF hydroxylases work in general and more importantly, (2) 
may become useful in future therapeutic investigations.  
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1.2.2 HIF Hydroxylases 
1.2.2.1 Prolyl Hydroxylase Domain (PHD) 
PHD is the mammalian homolog of the worm C. elegans HIF prolyl hydroxylase 
EGLN. It exists in four isoforms with PHD2 being the best-studied HIF hydroxylase on 
the basis of it being the most abundant isoform in human tissues[37-39,112]. PHDs are also 
given the name HIF-P4Hs to signify the fact that they hydroxylate specific proline 
residues of HIF at position 4[40]. However, ever since the group of Taylor discovered non-
HIF substrates in 2006, the name PHD is generally regarded as the most appropriate 
name for the enzyme[41,42].   
All isoforms of PHD contain the double-stranded β-helix (DSBH) jellyroll or 
cupin barrel core (Figure 1.3) characteristic of this highly conserved superfamily of 
enzymes that requires iron as a cofactor, and oxygen, α-ketoglutarate (αKG) and a 
primary substrate[37,38,43]. Ascorbate is also reported to be a cofactor requirement for 
optimal activity of the PHDs[40,64,124]. Deep within the enzyme core lies the mononuclear 
Fe(II) metal coordinated by the conserved two-histidine-one-carboxylate facial triad 
motif, HX(D/E)X….H, on one face of the octahedral arrangement (Figure 1.3)[44-47]. The 
remaining three coordination sites of the metal provides for the binding of the bidentate 
ligand, αKG, and O2 in the enzyme’s active state or water in the resting state. 
PHDs regulate the stability of human HIF-1α subunit by hydroxylation of the 
conserved proline residues, Pro402 and Pro564, located in the oxygen-dependent 
degradation (ODD) domain, which also overlaps with the NTAD[48-50,19-20,103] (Figure 
1.1B). All isoforms of PHD have been shown to hydroxylate Pro564 of HIF-1α while 
Pro402 is hydroxylated by PHD1 and PHD2[50]. Hydroxylation in any of the two prolines 
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is enough to make HIF-1α susceptible to proteasomal degradation via    
ubiquitination[48,50-54]. The hydroxylated proline residue, which is contained within the 
consensus binding motif LXXLAP, recruits the von Hippel-Lindau tumor suppressor 
protein or pVHL[55-57,19,20,50] via H-bond interactions with specific Ser and His residues 
located in the β domain of pVHL[58,59]. This interaction earmarks HIF-1α for destruction. 
The pVHL protein serves as the substrate recognition component of the cellular 
ubiquitination machinery. Upon pVHL binding to hydroxyproline, HIF-1α is linked to 
elongin B and C and other proteins that are part of the multiprotein E3 ubiquitin ligase 
complex (VHLE3), which ultimately targets HIF-1α for protein breakdown[60-62].  
The KM values for O2 of PHDs were determined to be 230-250 µM[40], which are 
well above the average intracellular oxygen concentration estimated to be around 4 to    
45 µM[43,123,125], making them well-suited as cellular oxygen sensors. The nonequilibrium 
conditions found for the enzymes mean that they can respond to small changes in the 
oxygen levels thus providing the link between intracellular oxygen concentration and the 
hypoxia response mechanism.[35] 
 
1.2.2.2 Factor Inhibiting HIF-1 (FIH-1) 
FIH-1 belongs to the same non-heme Fe(II)- and α-ketoglutarate (αKG)-
dependent family of dioxygenases as the PHDs[50, 24]. Unlike PHD however, FIH-1 is an 
asparaginyl hydroxylase that is only catalytically active as a homodimer (Figure 1.2)[63]. 
The dimerization buries a significant portion of the C-terminus of both monomer 
units[68,71] of the enzyme. FIH-1 is also more promiscuous than the PHDs in terms of 
substrate specificity. In addition to the well-defined target Asn residue located in a tight 
	   8	  
hairpin loop of the HIF-1α/CTAD substrate, FIH-1 has also been shown to hydroxylate 
Ser, His, Asp and Leu residues located in a similar loop configuration in proteins 
containing the conserved interaction motif, ankyrin repeat domain (ARD), such as the 
Notch proteins (Notch1 to 3), IκBα, NFκB, ASB4, Tankyrase-2, Rabankyrin-5, RNase L, 
MYPT1, p105 and ASPP2 among many others[78,81,82,113,114,116,117]. The biological 
significance of ARD hydroxylation by FIH-1 remains to be elucidated though several 




Figure 1.2 Dimer structure of FIH-1 highlighting the DSBH core (in violet) with the 
active site metal (red sphere) (1H2L, 2.25Å)[71]. Also shown is the close-up image of the 




activation and modification of cellular protein interactions[78,81]. The PHDs do not appear 
to be as promiscuous because only a handful of alternate substrates have been reported so 
far[41,83]. FIH-1 has been known to hydroxylate HIF-1α even under oxygen levels in 
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which the PHDs were reportedly inhibited[23,24,37,66,126]. This is quite consistent with the 
observed KM for O2 of FIH-1 (90 µM), which is lower than those of the PHDs[64].  
As mentioned before, FIH-1 hydroxylates a conserved asparagine residue, Asn803, 
in the CTAD of the HIF-1α subunit, which prevents the binding of the trans-coactivator 
p300/CBP[65-67,77]. In the absence of the trans-coactivators, HIF-1 cannot trans-activate 
genes downstream of the hypoxia response elements (HREs), which are the DNA regions 
where HIF binds. The HIF-1α/CTAD region (residues 786-826) is mostly unstructured 
when free in solution but it assumes an extended helical conformation when bound to the 
hydrophobic CH1 domain of p300/CBP[69]. The target Asn residue is normally buried 
within the extended helical structure adopted by HIF-1α/CTAD. One can see then how a 
hydroxyl group located in the pro-S position of the β-carbon of the Asn residue[70] would 
destabilize the helix and thus disrupt the hydrophobic interactions with the CH1 domain 
of p300/CBP, hindering its recruitment. 
Crystal structures of FIH-1 bound to substrate[68,71] revealed enzyme-substrate 
contacts that provide for catalysis. Prior to substrate binding, the unbound oxygen of the 
enzyme facial triad Asp201 residue forms a hydrogen bond with the iron-bound water 
ligand. This interaction was thought to play a key role in the coupling of substrate 
binding to turnover as the breaking of this H-bond (which occurs when native substrate 
binds) likely facilitates aquo ligand release[89,90,120]. This renders the active site O2-
reactive. In the presence of native substrate, Asp201 residue forms a new H-bond with the 
backbone amide of the substrate target residue, Asn803, thereby resulting to loss of the 
water ligand. Apparently, this phenomenon is only particular for FIH-1 and the ribosomal 
oxygenases (ROXs).[87] Aside from Asp201, an enzyme active site residue, Gln239, was 
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also found to form H-bond interactions with the side chain amide group of Asn803 
whereby it was hypothesized that Gln239 plays a functional role in tuning FIH-1 activity. 
Indeed, work from our group showed that this interaction is essential to properly position 
the target residue for subsequent hydroxylation[86,88]. Loss of the Gln239 interaction did 
not affect the first part of the catalytic cycle, which involves oxidative decarboxylation of 
αKG to form succinate and carbon dioxide. This indicates that certain active site 
elements are in place to ensure efficient catalysis of FIH-1, which strictly couples αKG 
oxidation with native substrate hydroxylation.  
Because the regulatory role of FIH-1 in hypoxia sensing lies in its ability to bind 
and hydroxylate HIF-1α in an oxygen-dependent manner, it becomes critical for the 
enzyme to ensure that αKG oxidation subsequent to HIF-1α binding will effectively 
result in HIF-1α hydroxylation. How FIH-1 exactly performs this is the general guiding 
question in this research. 
 
1.2.3 Proposed Reaction Mechanism of HIF Hydroxylases 
Data from several biophysical studies suggest a common mechanism for the non-
heme Fe(II)/αKG-dependent dioxygenases[89,90,92-94]. Scheme 1.1 shows the proposed 
consensus reaction for FIH-1, which follows a sequential ordered mechanism similar to 
the PHDs. Initially, the resting six-coordinate Fe(II) center of FIH-1 is bound by the 2-
histidine-1-carboxylate triad, specifically His199, Asp201 and His279 residues[71], on one 
face of the octahedral sphere and three water molecules on the opposite face. Metal 
binding is reversible for these enzymes as demonstrated by studies showing activity 
inhibition in the presence of iron chelators and cobaltous ions[37,44]. In the case of FIH-1, 
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the cosubstrate αKG displaces two of the equatorial water ligands upon binding and 
chelates Fe(II) in a bidentate mode via its C2 carbonyl oxygen and one of the C1 
carboxylate oxygens[71,89,90,94]. The C2 carbonyl is positioned trans to the facial   
 
Scheme 1.1 Proposed reaction mechanism for FIH-1 
 
triad carboxylate Asp201 residue. The C5 carboxylate oxygen is often found to interact 
with a nearby charged or polar residue located in the (R/K)XS motif, which is Lys214 
residue in the case of FIH-1[68,71]. Another residue, Thr196, is also found to form H-bond 
interactions with the C5 carboxylate end. Additional enzyme interactions with the 
uncoordinated C1 carboxylate of αKG form as well, specifically H-bond interactions 
with Asn205 and Asn294 residues, which were found to be important for the subsequent 
oxidative decarboxylation reaction of FIH-1[86].   Upon binding of the HIF-1α/CTAD 
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substrate, the target Asn803 residue does not chelate to the metal directly; instead it is 
strategically positioned right on top of the open sixth coordination site of Fe(II) trans to 
the distal facial triad His279 residue. Interactions between HIF-1α/CTAD and the facial 
triad carboxylate, Asp201, as well as several active site residues such as Gln239 also form 
upon binding[68,71]. These interactions ultimately result in the release of the last remaining 
axial water ligand, which in turn opens an empty coordination site for O2. Spectroscopic 
studies have demonstrated this change in the coordination state of the mononuclear Fe(II) 
from hexa- to pentacoordinate in the presence of substrate, which renders it more reactive 
to O2[72-74,90,94]. Thus, it seems that dioxygen binding and the subsequent activation is 
controlled by loss of the axial water, which in turn is triggered upon substrate binding. 
Once O2 is bound, the enzyme is primed for hydroxylation activity[75].   
Studies utilizing 18O isotope demonstrated that the hydroxylation reaction 
consumes both atoms of molecular oxygen[70,24,122]; one atom gets incorporated into the 
succinate product and the other one into the hydroxylated HIF-1α/CTAD substrate. Upon 
dioxygen binding to the quaternary (Fe(II)+ αKG)enzyme/substrate complex, the ensuing 
dioxygen activation is proposed to occur via electron transfer from Fe(II) to form Fe(III) 
superoxide based on the evidence of a radical-based mechanism for another related 
enzyme prolyl-4-hydroxylase[76] and the inhibition of prolyl hydroxylase with superoxide 
scavengers[121]. This nucleophile can then oxidize the keto-carbon of αKG, which 
produces carbon dioxide and succinate as well as a putative iron (IV) oxo (ferryl) 
intermediate. Transient and steady-state kinetics as well as spectroscopic studies allowed 
for the detection, characterization[95] and identification of this ferryl intermediate as the 
species responsible for the subsequent C-H cleavage step[96,97] in the catalytic cycle of the 
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related enzyme TauD. Unactivated C-H cleavage is proposed to proceed via hydrogen 
atom abstraction of the target residue to form a substrate radical intermediate and a 
putative Fe(III) hydroxo species. Finally, oxygen rebound mechanism[93] likely occurs 
resulting to primary substrate hydroxylation, specifically at the pro-S position[70] of the β- 
carbon of Asn803, and the subsequent recovery of the Fe(II) center ready for the next 
round of catalysis.  
1.3 Summary 
A huge wealth of information in the field of hypoxia sensing has been gathered 
for more than 12 years since the discovery of the HIFs in the early 90’s[7]. However, 
development of drugs specifically targeting the HIF hydroxylases for treatment of a wide 
range of hypoxia-related diseases are still considered in its infancy. As the HIF 
hydroxylases operate with similar mechanisms but have non-redundant physiological 
roles, it is crucial to be able to discriminate and selectively target one from the other. 
Studies that will provide any useful information for a more profound understanding of the 
structure and function of these enzymes continue to be important. 
This dissertation provides additional kinetic and dynamic insights into the 
substrate interactions and catalysis of FIH-1 that can potentially be used to improve 
future selective targeting studies.  
Chapter 2 showed our initial effort in identifying chemical frameworks that might 
be useful in the future design of selective inhibitors of HIF hydroxylases. 
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Chapters 3 and 4 attempted to address the broad question of how FIH-1 
effectively couples substrate binding to turnover, specifically how αKG oxidation 
subsequent to substrate binding results to HIF-1α/CTAD hydroxylation. Chapter 3 tells 
the investigation of the FIH-1 structural changes observed in the presence of the 
cosubstrate, αKG, while chapter 4 describes the characterization of an active site loop 
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FIH-1, factor inhibiting (hypoxia-inducible factor 1) HIF-1; 
HIF, hypoxia-inducible factor; 
HIF-P4H, (hypoxia-inducible factor) HIF prolyl 4 hydroxylase; 
IκBα, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha; 
NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
NTAD, N-terminal trans-activation domain; 
PAS, (periodic-aryl hydrocarbon receptor nuclear translocator-single-minded) Per-
ARNT-Sim; 
PHD, prolyl hydroxylase domain; 
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pVHL, von Hippel-Lindau tumor suppressor protein; 
ROX, ribosomal oxygenase; 
SRC-1, steroid receptor coactivator 1; 
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CHAPTER 2 
SCREENING αKG MIMICS FOR THE SELECTIVE INHIBITION OF FIH-1 
This chapter is part of a published paper: Flagg, S.C., Martin, C.B., Taabazuing, C. Y., 
Holmes, B.E., Knapp, M.J. (2012) Screening chelating inhibitors of HIF-prolyl 




2.1 Summary of Contributions to Published Paper   
 My primary contributions to this paper were the collection of the inhibition 
screening data and IC50 values for FIH-1 (Figure 1b and Table 1), a brief description of 
the activity assay method, and a very brief analysis of the inhibition results. 
 We would like to acknowledge Elsevier for allowing us to insert the actual article 
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Two primary O2-sensors for humans are the HIF-hydroxylases, enzymes that hydroxylate specific residues of
the hypoxia inducible factor-α (HIF). These enzymes are factor inhibiting HIF (FIH) and prolyl hydroxylase-2
(PHD2), each an α-ketoglutarate (αKG) dependent, non-heme Fe(II) dioxygenase. Although the two enzymes
have similar active sites, FIH hydroxylates Asn803 of HIF-1α while PHD2 hydroxylates Pro402 and/or Pro564 of
HIF-1α. The similar structures but unique functions of FIH and PHD2 make them prime targets for selective in-
hibition leading to regulatory control of diseases such as cancer and stroke. Three classes of iron chelators
were tested as inhibitors for FIH and PHD2: pyridines, hydroxypyrones/hydroxypyridinones and catechols. An
initial screen of the ten small molecule inhibitors at varied [αKG] revealed a non-overlapping set of inhibitors
for PHD2 and FIH. Dose response curves at moderate [αKG] ([αKG]~KM) showed that the hydroxypyrones/
hydroxypyridinones were selective inhibitors, with IC50 in the μM range, and that the catechols were generally
strong inhibitors of both FIH and PHD2, with IC50 in the low μM range. As support for binding at the active site
of each enzyme as the mode of inhibition, electron paramagnetic resonance (EPR) spectroscopy were used to
demonstrate inhibitor binding to the metal center of each enzyme. This work shows some selective inhibition
between FIH and PHD2, primarily through the use of simple aromatic or pseudo-aromatic chelators, and suggests
that hydroxypyrones and hydroxypyridones may be promising chelates for FIH or PHD2 inhibition.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
Cellular oxygen-sensing in metazoans is directly controlled by
non-heme Fe(II) α-ketoglutarate-dependent hydroxylases which hy-
droxylate the alpha-subunit of the hypoxia inducible factor (HIF-
1α).[1–3] As these HIF-hydroxylases are key regulators of angiogenesis
and basal metabolism and the progression of diseases such as cancer
and stroke, they are the subject of numerous inhibition studies.[4–6]
A large number of published inhibitors are derived from heteroaro-
matics such as 8-hydroxyquinoline, or N-oxalyl amino acids, such as
N-oxalylgycine (NOG),[5–7] each of which chelates the active-site Fe(II).
Although much attention has been paid to modifying these frameworks
to improve selectivity, switching focus to the chelating group can aug-
ment lead optimization, as shown forMMP [8]. Thismanuscript describes
our work to identify alternate chelators as leads for selective inhibition of
HIF hydroxylases (Chart 1).
The two best characterized of HIF-hydroxylases are the factor inhi-
biting HIF (FIH) and prolyl hydroxylase-2 (PHD2),[9–11] which hy-
droxylate specific amino acid residues on HIF-1α. Each enzyme uses
αKG to cleave O2, forming succinate, CO2, and a putative high-valent
[FeO]2+ oxidant in the first half reaction (Scheme 1). Subsequently,
this oxidant inserts theO-atom into a C–Hbond to form the hydroxylated
peptide. Despite their common underlying chemistry, PHD2 and FIH
transcriptionally repress HIF by different strategies. PHD2 hydroxylates
residues found in the oxygen-dependent degradation domain (ODDD)
of HIF-1α, Pro402 and/or Pro564, leading to proteasomal degradation of
HIF-1α. FIHhydroxylates Asn803 ofHIF-1α, found in theC-terminal trans-
activation domain (CTAD),which blocks p300 frombinding toHIF, there-
by repressing transcription.
The metal center of FIH and PHD2 are quite similar, as the Fe(II) is
coordinated by a His2Asp facial triad, bidentate αKG, and an H2O li-
gand.[12,13] This presents some challenge for inhibitor selectivity,
however selective inhibitors have been identified for other metal-
loenzyme families, such as lipoxygenases [14], and the MMPs [15].
In those cases, selectivity likely results from differences in the size
and shape of the closely related active sites. As the αKG-dependent
oxygenase family is large, selectively targeting an individual member
of that family may be challenging. Although both FIH and PHD2 repress
gene expression, their roles in health and disease are not redundant,
and selectively altering the activity of these enzymes is thought neces-
sary for targeted therapeutics. Selectivity between the HIF hydroxylases
may be achievable as the active site pockets differmarkedly between FIH
and PHD2. The available volume of the PHD2 active site when peptide is
bound (170 Å3) is similar to that of αKG (130 Å3) [13,16], whereas that
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of FIH is significantly larger (340 Å3) [12]. Consequently, FIH inhibitors
are often bulkier thanαKG, while PHD2 inhibitors tend to be planar aro-
matic rings [5].
The two coordination sites occupied by αKG are natural targets for
HIF hydroxylase inhibitors, due to the nature of their catalytic cycle
[17], and because metal chelation provides strong binding affinity.
As the C-5 carboxylate of αKG forms a salt-bridge with a buried
basic residue (FIH, Lys214; PHD2, Arg383), a pendant anionic group is
a common feature to the metal chelates that inhibit FIH and
PHD2.[5] Other structural distinctions relate to the bulk and polarity
of the amino acid residues lining each active site. The entrance to the
active site differs between PHD2 and FIH, where the C1-carboxylate
of αKG binds, and this may affect inhibitor binding. In FIH the C1-
carboxylate is stabilized by two hydrogen bonds from Asn205 and
Asn294, whichmay strictly constrain thewidth available for bidentate li-
gands to bind to FIH.[12] In contrast, the C1 carboxylate in PHD2 forms
an indirect hydrogen bond to Asp254 via a water molecule,[13] suggest-
ing that bidentate ligands may bind to PHD2 with an induced-fit in the
plane.
There is currently much effort to develop selective inhibitors for
the HIF hydroxylases as therapeutic agents [5,6] for ischemic and in-
flammatory disorders. Inhibitors that bind as αKG mimics while si-
multaneously recognizing the active site may be the most promising
for FIH and PHD2, both to minimize side-effects from other αKG-
oxygenases, as well as to ensure selectivity toward a specific HIF hy-
droxylase. N-oxylylglycine (NOG) and dimethyl N-oxalylglycine
(DMOG) are structurally similar to αKG, and inhibit both PHD2 and
FIH, but their selectivity is poor. More selective inhibitors of FIH
were prepared by synthesizing chiral N-oxalyl amino acids, structural
derivatives of NOG, which are selective for FIH due to the larger active
site of FIH.[7] Quite different compounds have been reported as po-
tent PHD2 inhibitors (IC50~1 μM) including the heteroaromatic iso-
quinolines[18,19], benzimidazoles[20], and imidazo[1,2-a]pyridines
[21]. Several of these inhibitors have been shown to bind to the re-
spective active site Fe(II) by X-ray crystallography, showing that a
dominant mechanism of action is metal binding within the active
site.[7,13,20,22,23].
Despite the successes in targeting PHD2 and FIH, most efforts have
focused on a small number of Fe(II) chelating groups. This may limit
therapeutic development, because exploring different metal chelators
can lead to increasingly more effective inhibitors, as shown for other
metalloenzymes.[8] In the present work, we screened a small library
of chelating structures for their ability to inhibit FIH and PHD2, with
particular emphasis on bidentate chelators as structural mimics of
αKG. We were particularly interested in HOP/HOPO structures, as
these chelates seemed to hold promise as HIF-hydroxylase inhibitors
based on their use in other metalloenzyemes, such as matrix metallo-
proteases [24] and other αKG oxygenases.[25,26].
Fig. 2. a) X-Band EPR of (CuII)PHD Samples. PHD (0.65 mM), CuSO4 (0.60 mM), biden-
tate ligand (0.60 mM) in 50 mM HEPES pH 7.50. 9.598 GHz frequency, 5 mW power,
5 G modulation amplitude, 100 GHz modulation frequency, 81 ms time constant at
77 K.b) X-Band EPR of (CuII)FIH Samples. FIH (0.65 mM), CuSO4 (0.60 mM), biden-
tate ligand (0.60 mM) in 50 mM HEPES pH 7.50. 9.593 GHz frequency, 5 mW
power, 5 G modulation amplitude, 100 GHz modulation frequency, 163 ms time con-
stant at 77 K.





































Fig. 1. a) Initial inhibitor screening for PHD2. Assays included PHD2 (1.5 μM), αKG (10
or 200 μM), Fe(NH4)2SO4 (20 μM), ascorbate (2 mM), ODDD (60 μM) and inhibitor
(100 μM). All components with exception of ODDD were mixed and assays were initi-
ated with ODDD at 37 °C.b) Initial inhibitor screening of FIH. Assays included FIH
(0.5 μM), αKG(10 μM or 500 μM), CTAD (66 μM), ascorbate (2 mM), FeSO4 (500 μM)
and inhibitor (100 μM). All components were mixed except FIH, and assays initiated
with the addition of FIH.
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The prime substrate for FIH was a 39-residue peptide corresponding
to HIF-1α788-826 with a Cys800➔Ala point mutation, which corresponds
to the C-terminal transactivation domain of HIF-1α (CTAD). The CTAD se-
quence used (Asn803 in bold) was DESGLPQLTSYDAEVNAPIQGSRNLLQ-
GEELLRALDQVN, which was unmodified at the peptide termini. CTAD
peptide was purchased from EZBiolabs as a desalted product, and was
further purified by reverse-phase HPLC.
The peptide substrate used for PHD2was a peptide derived from the
natural sequence of HIF-1α556-574, which is the C-terminal oxygen de-
pendent degradation domain (ODDD) of HIF-1α. The peptide sequence
used (Pro564 in bold)was DLDLEALAPYIPADDDFQL, in which the termi-
niwere notmodified, and the naturalMet residueswere replaced byAla
at the underlined positions. ODDD was purchased from GL Biochem
(Shanghai) LTD as a 99% purity peptide, and was used as received (dis-
solved in 50 mM HEPES pH 7.00) for PHD2 activity assays.
Compounds were purchased from commercial sources and used as
receieved. HOP-COOH, HOP-OH, and DHP were purchased from Sigma-
Aldrich; NOP was purchased from Fluka; pyCN, HOP-Me, HOPO, MeCat,
BuCat, NCat were purchased from Acros.
2.2. Protein expression, purification, and activity
Recombinant human PHD2 was expressed and purified as the cat-
alytic domain (residues 177–426), similar to previous protocols [13].
PHD2 was expressed as an N-terminal GST fusion in E. coli BL21(DE3)
cells, using a pGEX vector (Stratagene). The GST-PHD2 was purified
using affinity chromatography (GE Bioscience GSTrap), then the GST
removed by thrombin. Purified protein was then buffer exchanged
into 50 mM HEPES pH 7.00. Protein purity was assessed by SDS-PAGE
gel and mass spectrometry.
Recombinant human FIH-1 was expressed from E. coli with an N-
terminal His6 tag, which was removed by thrombin digestion after puri-
fication, as previously described.[27] Exogenous metal was removed
with EDTA incubation and then size-exclusion chromatography, resulting
in the FIH-1 dimer.
2.3. Activity assays
PHD2 activity assays were conducted using 1.5 μM PHD, 2 mM
ascorbic acid , 0–500 μM α-ketoglutarate and 20 μM ammonium iron
(II) sulfate in 50 mM HEPES pH 7.00, 37.0 °C. Assays were initiated
by the addition of ODDD and time points were extracted and
quenched in a matrix consisting of 4-α-cyano hydroxycinnamic acid
with a 2:1 ratio of acetonitrile and 0.2% trifluoroacetic acid. Samples
were then analyzed on a Bruker Daltonics Omniflex MALDI-TOF and
the results were interpreted as a ratio of the parental peak to the hy-
droxylated peak which exhibits a mass shift of 16 from the parental.
Themole fraction of product (χODDD-OH) was obtained from the result-
ing spectra by comparing the relative intensities of the peak at
2156 m/z, corresponding to (ODDD+Na)1+, to the peak at 2172 m/z,
corresponding to (ODDD+O+Na)1+. Product formationwas calculated
using [ODDDOH] = χ(ODDD-OH) x [ODDD]0, and used to determine initial
rates. Dose response curves were assayed with 1.5 μM PHD2, 2 mM
ascorbic acid , 10 μM αKG and 20 μM ammonium iron (II) sulfate in
50 mM HEPES pH 7.00, 37.0 °C. For each inhibitor concentrations of up
to 1 mM were used to obtain the the dose response curves. Inhibitors
were dissolved in 50 mMHEPES pH 7.00 forworking stocks for all assays.
FIH assays were conducted in 50 mM HEPES pH 7.50, at 37.0 °C.
The initial screens included 2 mM ascorbate, 10 μM or 200 μM αKG,
20 μM FeSO4, 80 μM CTAD, 100 μM inhibitor, and 0.5 μM FIH. Assay
componentsweremixed and incubated in 45 μL at 37 °C for 5 min, before
initiating the reaction with 5 μL of FIH. Dose–response assays were per-
formedunder similar conditions, using 10 μMαKGandvarying the inhib-
itor concentration (0–500 μM). Aliquots (5 μL)were quenched in 20 μL of
MALDI matrix (3,5-dimethoxy-4-hydroxycinnamic acid in 75% CH3CN/
H2O containing 0.2% formic acid). FIH mediated hydroxylation of the
Scheme 1. Net reaction for FIH (R-H=Asn) and PHD2 (R-H=Pro).
Chart 1. Inhibitor classes tested. CNP (3-Cyano-6-methyl-2(H) pyridinone), NOP (2-
Hydroxypyridine 1-oxide), DHP (2,3-Dihydroxypyridine), Hop-OH (5-Hydroxy-2-
hydroxymethyl-4-pyrone), Hop-COOH (5-Hydroxy-4-oxo-4H-pyran-2-carboxylic acid),
Hop-Me (3-Hydroxy-2-methyl-4-pyrone), Hopo (3-Hydroxy-1,2-dimethyl-4(1H)-
pyridinone, 4NCat (4-Nitrocatechol), MeCat (4-Methylcatechol), BuCat (4-tert-
Butylcatechol).
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CTAD substrate wasmonitored by the relative intensities of the substrate
(4255 m/z) and product (4271 m/z) peaks using a Bruker Daltonic
Ominoflex MALDI-TOF.
2.4. Electron paramagnetic resonance
The binding constant for Cu2+ binding to FIH was measured by a
fluorescence quenching titration in which 1 mM CuSO4 (50 mM HEPES,
pH 7.50, containing 1 mM citrate) was titrated into a solution of FIH
(20 μM in 50 mM HEPES, pH 7.50, 20 °C) containing αKG (100 μM)
and citrate (1 mM). The method followed was similar to that reported
previously for Co2+ binding to FIH [28], with the exchange of metal
salt. Attempts at measuring Cu2+ binding to PHD2 by fluorescence
quenching were unsuccessful due to a slight turbidity interfering with
the fluorescence readings.
X-Band EPR spectra were recorded on a Bruker Elexsys E-500 ESR
Spectrometer equipped with DM4116 cavity, with samples placed in
a liquid-nitrogen finger dewar. Samples were prepared by combining
each enzymewith CuSO4 in ratio of 1:0.9 then addingαKG or putative
inhibitor as indicated. In each of the samples, the CuSO4 solution was
slowly added in 0.5 μL increments to prevent protein precipitation.
Spectra were acquired at 5 mW power, 5 G modulation amplitude,
100 GHz modulation frequency.
3. Results and discussion
3.1. Initial screen
An initial screening of all compounds at 100 μM concentration was
performed to identify inhibitors for PHD2 and FIH that were likely to
exhibit IC50 in the micromolar concentration range (Fig. 1). We used a
low-throughput screen in which the initial rate of turnover was mea-
sured using a discontinuousMS analysis. Such a labor intensive approach
was necessary in order to accurately measure peptide hydroxylation
kinetics, as we were unable to obtain satisfactory results using the pub-
lished fluorescence assay for αKG depletion [29]. As the αKG depletion
assay is a subtractive assay, it is difficult to accurately measure initial
rates when theαKG concentration is depleted by less than 10% from ini-
tial conditions. A related concern is that the αKG depletion assay does
not directly measure peptide hydroxylation, and therefore measures
the sum of coupled and uncoupled turnovers.
Initial screens were performed at sub-saturating concentrations
([αKG]~KM) in order to identify inhibitors under non-stringent condi-
tions. The Michaelis constant for αKG indicated stronger αKG affinity
for PHD2 (KM=7±2.5 μM) than for FIH (KM=22±6 μM) [28]. These
screens indicated identified compounds from each structural class that
would be likely to exhibit IC50b100 μM toward PHD2 or FIH. Two com-
pounds from theHOP/HOPOclass and two catecholswere effective inhib-
itors of PHD2 at sub-saturating α-KG concentrations. A similar variety of
compounds were effective inhibitors of FIH at sub-saturating αKG. The
non-overlap between inhibitors for FIH and PHD2 strongly suggested
that one or more of these compounds would be selective toward these
enzymes.
Amore stringent screenwasperformedusing saturatingαKG concen-
trations ([αKG]>4 KM), as less effective inhibition at elevated [αKG] is a
hallmark for competitive inhibition. Several compounds were less effec-
tive inhibitors under stringent conditions, suggesting that the inhibition
mode was competitive for αKG. For FIH, each of the HOP/HOPO com-
pounds (5, 6, 7, 8), as well as two of the catechols (9, 10), exhibited this
pattern. For PHD2, only two of the HOP/HOPO compounds (5 and 7)
and one of the catechols (10) exhibited this competitive pattern.
3.2. Dose response
Full dose–response curves were analyzed for each compound to-
ward FIH and PHD2 using a sub-saturating concentration of αKG,
with most compounds displaying a simple dose–response indicative
of single-site binding (Table 1). The exceptions are the dose–response
curves for compounds HOPO and BuCat toward PHD2, which indicated
two-binding sites. In general, the dose–response curveswere consistent
with the initial screens, as compounds from each structural class inhib-
ited FIH and PHD2 with IC50b500 μM.
Most compounds tested were more effective inhibitors of PHD2
than of FIH, likely reflecting the structural differences between the ac-
tive sites. Each dose–response assay used the same sub-saturating
[αKG] / KM(αKG) ratio (~ 1.2), thereby controlling the most important
variable in comparing the IC50. Selectivity likely reflects the preference
of aromatic chelators to bind to PHD2,whereas bulky compounds such
as N-derivatized NOG preferentially bind to FIH.
The IC50 trends suggested that these metal chelators distinguished
FIH from PHD2. From the relative trend of IC50 among the catechols, it
appeared that FIH was more tolerant of sterically bulky substitutents
than PHD2, as predicted from the volumes of each active site cavity.
Notably, FIH did not significantly discriminate MeCat (9) from BuCat
(10), whereas PHD2 discriminated these compounds by roughly
ten-fold.
Pyridine-based compounds exhibited a wide range of IC50 values,
with NOP and DHP of similar effectiveness toward each enzyme.
The pyCN exhibited no inhibition toward PHD2 nor FIH, suggesting
that bidentate binding as an αKGmimic was necessary for strong inhi-
bition. This may also reflect a preference for O-donors over N-donors, as
seen previously.[30]
The HOP/HOPO class of compounds demonstrated a wide range in
inhibitor effectiveness with IC50 values varying by a factor of more
than 100-fold. Both bulk and functional group played a role in inhibi-
tion for both FIH and PHD2, consistent with an induced-fit of the in-
hibitor to the active site. The most effective HOP inhibitor for both
PHD2 and FIH was the HOP-COOH, which structurally resembles a
cis-isomer of αKG. It is likely that HOP-COOH would be able to form
a salt-bridge with the buried basic residue found in both PHD2
(Arg383) and FIH (Lys214). The HOP-OH compound exhibited dimin-
ished effectiveness toward each enzyme, consistent with the removal
of one part of this salt bridge.
The dimethyl-substituted HOPO was a better inhibitor than the
methyl-substituted HOP-Me for each enzyme. This likely reflects the
inherently stronger binding of the HOPO framework to divalent
metals as compared to the HOP framework. Interestingly, HOPO has
been reported as an antifibrotic agent in cell-based screens targeting
the collagen prolyl hydroxylase [25], but no report of its use against
PHD2 has appeared until now.
Several metal chelators bind to the active site of HIF hydroxylases,
as mimics of αKG. Examples include N-oxalylglycine (NOG) and
tricarboxylic acid cycle intermediates,[7,31,32] and isoquinoline de-
rivatives.[18,19] Greater efficacy and selectivity have been achieved
by derivatizing the chelate framework – for example, derivatizing
Table 1
IC50 toward FIH and PHD2.
Compound PHD2 FIH
IC50 (μM) IC50 (μM)
1 CNP > 1000 > 1000
2 NOP 3 10
3 DHP 5 75
4 HOP-OH 400 170
5 HOP-COOH 30 50
6 HOP-Me 1000* 70
7 HOPO 40 30
8 4NCat 6 10
9 MeCat 4 50
10 BuCat 30* 120
*For HOP-Me the concentration to achieve exactly half the maximal rate is 16 μM, for
BuCat it is 1 μM, the values in the table are reflective of the second inhibitory event.
28 S.C. Flagg et al. / Journal of Inorganic Biochemistry 113 (2012) 25–30
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the NOG backbone with canonical amino acid sidechains revealed
that D-isomers were selective inhibitors of FIH, with N-oxalyl-D-
phenylalanine (KI=90 μM) the most effective inhibitor from that
study [7]. Similarly, elaborated isoquinolines [18,19] are potent inhibi-
tors of PHD2. These reports, and scattered reports of other chelators as
HIF hydroxylase inhibitors, indicate that targeting both themetal center
and the active site can enhance selectivity [21,30]. These studies under-
score the promise of a dual-targeting approach to inhibitor design.
3.3. EPR spectra of PHD2 and FIH
EPR was used to monitor ligand binding to the active site of both
PHD2 and FIH (Fig. 2). As the nativemetal is unsuited for X-band perpen-
dicularmode EPR (Fe(II) likely has S=2), enzymeswere constitutedwith
Cu(II), a d9metal that is spectroscopically observable by conventional EPR
methods and which binds tightly to FIH (KD=5.8!10!12 M). Each en-
zyme was constituted with a representative inhibitor from each class,
DHP (3), HOPO (7) and 4NCat (8) (Table 2). With Cu(II), the magnitude
of gII and AII are the most telling parameters as they are very sensitive
to the geometry and identity of the ligands in the XY plane of type-2
copper centers such as those found in Cu-constituted αKG-dependent
hydroxylases [33].
The spectrum of (Cu)PHD2 exhibited moderate g-anisotropy (g"=
2.06, gII=2.29), and large hyperfine coupling (A||=148 G), due to coor-
dination by theHis2Asp facial triad aswell as likely by 3waters. The line
widths were rather broad, consistent with some disorder of the metal
center due to the water ligands. With the formation of (Cu+αKG)
PHD2, g-anisotropy increased (g"=2.07, gII=2.35) and the Cu(II) hy-
perfine coupling constant decreased (A||=142 G), consistent with an
N/O-rich coordination sphere with anionic ligands.[33]
The spectral features for (Cu)FIH and (Cu+αKG)FIH were very
similar to the those observed for the analogous PHD2 samples
(Table 2), as seen previously for FIH and related αKG-dependent oxy-
genases.[28,34] Additionally, binding of either αKG or any of the in-
hibitors led to a sharper line shape and the appearance of additional
fine structure near g=2.07 for both PHD2 and FIH, consistent with
the expulsion of waters form the coordination sphere, and a more or-
dered metal center.
The EPR data indicated that the representative inhibitors bound to
the metal center in both PHD2 and FIH as an αKG mimic. This is con-
sistent with the moderate level of inhibition observed toward both
enzymes. A notable difference between PHD2 and FIH is the spread
in the magnitude of A||, as a decrease in this parameter indicates that
the four ligands in the XY plane are distorted away from a planar ar-
rangement. The hyperfine splitting was relatively invariant for all
(Cu+ligand)PHD2 samples (A||=142 – 148 G), indicating that the
geometry about the Cu(II) center was relatively insensitive to replace-
ment of αKG for 2 H2O or any of the representative inhibitors. In
contrast, the hyperfine splitting for FIH varied widely (A||=134 –
152 G) upon similar ligand replacement, indicating that Cu(II) in the
FIH active site was subject to greater geometric distortion than in
PHD2. This may arise from sterics within the active site of PHD2 limit-
ing the orientation of the metal ligands, whereas there are fewer such
clashes within the larger FIH active site.
4. Conclusions
This work identified simple aromatic or pseudo-aromatic chelators
as effective inhibitors of PHD2 and FIH, thereby expanding the number
of chelate structures used for therapeutic development. Since both
PHD2 and FIH share a similar Fe(II) binding site containing a His2Asp fa-
cial triad, inhibitor selectivity likely reflects secondary contacts within
the active site. For example, EPR of Cu(II) forms of the enzyme indicated
that the PHD2 active sited permitted less variation in ligand planarity
than FIH. This more defined active site in PHD2 led to greater variation
in IC50 than observed for FIH.
Selectivity toward PHD2 was enhanced by the presence of polar
functional groups on the chelate ring, suggesting a direction for fur-
ther refinement of selective and potent PHD2 inhibitors. In particular,
theHOP/HOPO class of chelatesmay be promising for further elaboration
of selective inhibitors toward FIH or PHD2, due to their wide variation in
IC50 in response to functional group polarity and bulk. Inasmuch as HOP/
HOPO-based structures have been used as the foundation for metallo-
enzyme inhibitors and medicinal inorganic compounds,[24,35] basing
further inhibitors on theHOP(O) frameworkmay lead to increasingly se-





CTAD C-terminal transactivation domain of HIF-1α;
DHP 2,3-dihydroxypyridine
ESI-MS electrospray ionization mass spectrometry;
FIH-1 the factor inhibiting HIF;
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;










PHD2 prolyl Hydroxylase domain 2
αKG alpha-ketoglutarate
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Table 2
EPR Spectral Parameters for (Cu)FIH and (Cu)PHD2 Samples. Parameters were deter-
mined using Spincount.
EPR Parameters
gII g" AII (G)
(Cu)PHD 2.06 2.29 152
(Cu+αKG)PHD 2.07 2.34 143
(Cu+DHP)PHD 2.07 2.31 145
(Cu+HOPO)PHD 2.07 2.31 147
(Cu+4Ncat)PHD 2.07 2.31 147
(Cu)FIH 2.06 2.30 143
(Cu+αKG)FIH 2.07 2.35 136
(Cu+DHP)FIH 2.07 2.32 137
2.33 130
(Cu+HOPO)FIH 2.07 2.33 137
(Cu+4Ncat)FIH 2.07 2.32 141
2.27 131
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Figure 2.1 Dose-response assay curves for FIH-1 fitted to a one-component binding 
equation in OriginPro. The reaction mix contained the following components: 0.5 µM 
enzyme, 20 µM FeSO4, 2 mM ascorbate, 10 µM αKG, 80 µM HIF-1α/CTAD, and 0-500 
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CHAPTER 3 
αKG-INDUCED CONFORMATIONAL CHANGES IN FIH-1: IMPLICATIONS 
FOR SUBSTRATE BINDING, CATALYSIS, AND REGULATION 
 
3.1 Introduction  
Factor inhibiting hypoxia-inducible factor-1 (FIH-1) is an Fe(II)/α-ketoglutarate-
dependent dioxygenase that modulates hypoxia-inducible factor-1 (HIF-1) in an oxygen-
dependent manner via hydroxylation of Asn803 in the C-terminal trans-activation domain 
(CTAD) of the HIF-1α subunit[26,33]. This single amino acid modification leads to 
transcriptional repression of HIF-1 under normal oxygen conditions[1,2]. The fact that 
FIH-1 modulates HIF-1 makes it an attractive drug target for the treatment of hypoxia-
related diseases such as anemia, stroke, heart disease and cancer. However, the presence 
of other related oxygenases in the cells necessitates selective therapeutic targeting, which 
is challenging given the exquisite similarity of the active sites. Thus, studies that will 
probe the molecular details of the substrate interactions of FIH-1 can potentially uncover 
subtle differences that can be exploited for the future development of highly selective 
drugs.  
 The nature of substrate binding for FIH-1 is thought to follow a sequential 
binding order, which is based on the consensus reaction mechanism proposed for the non-
heme iron dioxygenases (Scheme 1.1)[48-52]. A recent study in the lab supported this 
binding order for FIH-1[42] wherein the essential cofactor αKG binds directly to Fe(II) 
prior to HIF-1α/CTAD substrate. The substrate does not chelate the metal directly but 
binds right on top of Fe(II), which triggers aquo ligand release from the sixth 
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coordination site trans to the distal facial triad His279 residue. O2 then binds in the vacant 
site and gets activated at an appreciable rate as observed for the related enzymes TauD, 
CS2, and SyrB2[46,57,58].   
In an effort to uncover the unique substrate interactions of FIH-1 for future 
therapeutic investigations, the available crystal structures were closely inspected. 
Superposition of the crystal structures for the apo (1IZ3, 2.80 Å)[47] and various ligand-
bound enzyme forms – αKG-bound (1MZF, 2.40 Å; 1H2N, 2.84 Å)[6,7] and αKG/CTAD-
bound (1H2L, 2.25 Å)[7] – did not reveal large-scale displacements in the protein 
backbone structure of FIH-1 but only showed sidechain reorientations within the active 
site. Except for a few others like CurA[59], no significant conformational changes in the 
protein backbone were also observed upon Fe(II) or αKG binding as seen in the crystal 
structures of PHD2 and several of the αKG dioxygenases[56,20,14]. Nonetheless, it has been 
shown via NMR, at least for PHD2 and AlkB, that binding of αKG results in a 
significantly more rigid structure[9,10,15]. Moreover, it has been noted by several groups 
that the presence of αKG or an αKG mimic like N-oxalylglycine (NOG) facilitated the 
formation of crystals which is attributed to its stabilizing effect on the protein fold[6,7,11]. 
Despite the lack of crystallographic evidence, a molecular dynamics study of FIH-1 
revealed substantial structure stabilization in the presence of αKG[53]. In our lab, we have 
observed the drastic quenching of the intrinsic fluorescence intensity of FIH-1 upon αKG 
addition, which is a clear indication that some αKG-dependent conformational changes, 
at least within the environment of the reporter tryptophan residues, are happening to the 
enzyme. A similar observation was also noted for the related enzymes, TfdA and 
XanA[43,62]. The authors have, in fact, utilized the observed significant Trp quenching to 
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probe αKG binding. Based on all these studies, we postulated that αKG binding induces 
conformational changes within the active site of FIH-1, which likely results to structural 
stabilization. 
  When FIH-1 was first identified as a protein that interacts with HIF-1 from yeast 
two-hybrid assays, Mahon and co-workers[32] made the interesting observation that in 
vitro, the 41-mer HIF-1α/CTAD 786-826 did not bind FIH-1 under the GST pull-down 
assay conditions which do not include any cofactor, and that it will only bind sufficiently 
if the extra residues 576-785 (which comprises the inhibitory domain of HIF-1α) are 
included. However, it was found in later studies that even without the inhibitory domain, 
the 39-mer HIF-1α/CTAD 788-826 peptide is a satisfactory stand-alone substrate for 
FIH-1 activity assays provided the cofactors Fe(II) and αKG are included. The group of 
Lando et al.[33] also made the important observation that in addition to preventing p300 
binding to HIF-1α/CTAD via hydroxylation, FIH-1 itself could physically block the 
association. The caveat however, is that FIH-1 could not directly compete with p300 for 
HIF-1α/CTAD binding unless the cofactors Fe(II) and αKG are present. These 
observations strongly imply that the binding of αKG to metal-bound FIH-1 is a 
prerequisite to HIF-1α/CTAD binding.  A quite similar implication was also hinted at 
when Zhou et al.[57] observed the lack of spectroscopic changes at the metal center of the 
related enzyme clavaminate synthase 2 (CS2) upon addition of the native substrate in the 
absence of αKG. They implied, however, that the results do not rule out substrate binding 
as it can also mean that the bound substrate simply did not affect the metal center[57]. 
Nevertheless, the hypothesis that αKG is required for optimal substrate binding to FIH-1 
is not implausible. Our hypothesis then is that αKG binding induces conformational 
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changes within the active site resulting to FIH-1 stabilization and that this stabilization is 
optimal for HIF-1α/CTAD binding. The postulated model will potentially support and 
provide a structural basis for the sequential ordered binding mechanism thought to 
operate for this enzyme.  
To test this hypothesis, we used thermal shift assays, global hydrogen/ deuterium 
exchange, intrinsic protein fluorescence experiments and limited proteolysis coupled to 
mass spectrometry. Here, we show evidence of αKG-induced conformational changes in 
FIH-1. We demonstrate that the presence of αKG stabilizes the enzyme, which has 
important ramifications on the nature of substrate binding, on catalysis, potentially on 
enzyme regulation as well as on the design of future selective inhibitors for FIH-1. 
 
3.2 Experimental Procedure 
3.2.1 Materials 
 The substrate used for FIH-1 is a 39-mer peptide corresponding to human HIF-1α 
788-826 C-terminal activation domain (CTAD). The sequence used (Asn803 in bold and 
underlined) was DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN with the 
termini kept unmodified. It was obtained from EZBiolab (Carmel, IN) as a desalted 
product. The synthetic peptide contained a Cys à Ala mutation that still preserves the 
hydrophobic character but eliminates any unwanted side-chain interaction with the thiol 
group. The peptide was purified prior to use by RP-HPLC. It was dissolved in 25% 
acetonitrile (CH3CN)/0.2% trifluoroacetic acid (TFA) and purified to at least 95% purity. 
The concentration of the peptide is determined by monitoring the absorbance of Tyr 
residue at 293 nm (ε = 2400 M-1cm-1) in 0.1 M NaOH[38]. 
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Iron (II) sulfate (FeSO4), manganese sulfate (MnSO4), and 3,5-dimethoxy-4-
hydroxycinammate (sinapinic acid) were purchased from Acros Organics (Morris Plains, 
NJ). The rest of the chemicals and the snakeskin dialysis membrane were obtained from 
Fisher Scientific (Fair Lawn, NJ). Molecular weight cutoff filters (MWCO) were 
obtained from Millipore (Burlington, MA) and Vivaspin20 ultrafiltration tubes were from 
Vivascience Sartorius (Gottingen, Germany).  
3.2.2 FIH-1 Expression and Purification 
BL21-DE3 E. coli cells containing the wild-type FIH-1/pET28a plasmid were 
grown in Luria-Bertani broth (25 g/L) supplemented with 30 µg/mL kanamycin at 37°C 
with constant shaking. The cells were induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) when the OD600 reached 0.5-0.7 and then further incubated 
at 37°C for 5 h before harvesting the cells by centrifugation. Cell lysis was facilitated by 
the use of lysozyme (1 mg/mL) and sonication on ice for 30 mins with 30 secs break 
between each burst cycle. Cell debris was removed by centrifugation at 15000 rpm 
(26786g), 4°C for 45 mins. The crude cell lysate was dialyzed against 10 mM Tris, pH 
8.0 at 4°C and then clarified by centrifugation at 15000 rpm (26786g), 4°C for 10 mins. 
Purification of the His-tagged enzyme was carried out by Ni-affinity chromatography 
using the BioRad BioLogic LP pump system. The enzyme was eluted out using 250 mM 
imidazole/50 mM NaH2PO4/300 mM NaCl, pH 8.04 buffer at a flow rate of 3 mL/min. 
The enzyme eluate was buffer-exchanged against 10 mM Tris, pH 8.0 at 4°C to reduce 
the imidazole concentration. The concentration of the protein was estimated by UV 
absorbance at 280 nm using ε280 = 1.22 mL mg-1cm-1 [37].  The His-tag attached to the  
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N-terminus was then removed by incubation of the enzyme with thrombin (0.5 U/mg 
protein) for 36 h at 4°C. The cleaved enzyme was obtained by affinity chromatography 
and was incubated with 50 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0 at 4°C 
overnight.  The protein sample was then concentrated at 4°C using the Amicon pressure 
concentrator fitted with a 30kDa MWCO filter and finally with the Vivaspin20 
ultrafiltration tube before it was loaded into the Sephadex G75 resin column to obtain the 
FIH-1 dimer. The purity of the enzyme was checked by SDS-PAGE.  
3.2.3 Activity Assays  
FIH-1 activity was assayed by following the formation of the hydroxylated CTAD 
peptide substrate over a specified period of time using the MicroFlex MALDI-TOF MS 
(Brucker Daltonics, Billerica, MA). Unless otherwise specified, steady state assays were 
done under ambient O2 concentrations at 37.0°C in 50 mM HEPES (pH 7.02) maintained 
at a total ionic strength of 100 mM using NaCl. The reaction buffer contained 500 µM 
αKG, 2 mM ascorbate, and 50 µM FeSO4. All the buffer constituents were mixed and 
initially incubated at 37.0°C for 3 mins, after which the reaction was initiated by adding 
enzyme to a final concentration of 0.5 µM. The reaction was quenched by addition to    
20 µL of 75% CH3CN/0.2% TFA saturated with the MALDI matrix, 3,5- dimethoxy-4-
hydroxy-cinnamate, at various time points ranging from 20-120 secs. To determine the 
amount of hydroxylated CTAD, the product of the total CTAD concentration and the 
ratio of the peak intensity for the hydroxylated product relative to the overall peak 
intensities (combined intensities of the parent and hydroxylated peaks) was calculated. 
The amount of hydroxylated CTAD was plotted versus time and the initial rate was 
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determined from the slope of the plot. 
3.2.4 Fluorescence Quenching Experiments 
 The samples in the cuvette for fluorescence experiments contained one or two or 
all of the following components: 2 µM FIH-1, 50 µM MnSO4, 500 µM αKG, 200 µM 
HIF-1α/CTAD in 50 mM HEPES pH 7.0 with the total ionic strength maintained at 100 
mM using NaCl. All samples were mixed thoroughly and then incubated at room 
temperature (~23°C) for at least 3 mins prior to fluorescence measurement with a Photon 
Technology International Quantamaster-4 SE fluorimeter. Tryptophan fluorescence 
emission scan was done at the wavelength range of 300-375 nm using excitation and 
emission slit widths of 0.1 mm and 2.5 mm respectively. The excitation wavelength used 
was 295 nm and the emission intensity at 330 nm was monitored. 
 For binding experiments, the same samples were prepared without HIF-1α/CTAD 
substrate. The titrant solution contained 2.8 mM HIF-1α/CTAD, 2 µM FIH-1, 50 µM 
MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0 with the total ionic strength maintained 
at 100 mM using NaCl. The emission spectra generated were baseline-corrected with the 
buffer blank and were smoothed using the adjacent-averaging method in OriginPro. The 
titration data were obtained by recording the magnitude of emission intensity at 330 nm. 
The binding data was fitted to a modified form of the Hill plot equation where n and Vmax 
are fixed at unity and K is the binding affinity: 
                                             𝑦 =    !!"#  ×  [!]
!
!![!]!
                      Equation 3.1  
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3.2.5 Thermal Shift Experiments 
 Samples for the melt curve experiments contained one or two or all of the 
following components: 5 µM FIH-1, 50 µM MnSO4 and 500 µM αKG in 50 mM HEPES 
pH 7.0. For each sample, 45 µL of the master mix was distributed to each well in the 96-
well qPCR microplate and 5 µL of freshly prepared 5X SYPRO Orange (Sigma-Aldrich, 
5000X stock diluted in dimethylsulfoxide) was thoroughly mixed in. The microplate was 
sealed with a Microseal adhesive film, briefly spun and immediately loaded onto a Bio-
Rad CFX Connect RT-PCR machine and the samples were heated at a rate of 1°C/min 
from 20°C to 90°C. The fluorescence intensity (excitation wavelength: 450-490 nm; 
emission wavelength: 560-580 nm) was monitored as a function of temperature. The Tm 
was determined using the positive first derivative plot of the data points generated. 
3.2.6  Global Hydrogen/Deuterium Exchange with Mass Spectrometry 
 For the HDX-MS experiments, a portable icebox equipped with an injection port 
and a C4 RP column was used. It was connected to the HPLC pump on one end and the 
ESI-TOF MS instrument on the other. All samples were initially prepared on ice prior to 
incubation at room temperature (26°C).  The different samples contained one or two or 
all of the components upon final dilution into ammonium acetate buffer: 20 µM FIH-1, 
50 µM MnSO4, 500 µM αKG, 200 µM CTAD in 50 mM HEPES pH 7.0 with the total 
ionic strength maintained at 100 mM with NaCl. A master mix for each of the different 
samples were initially prepared, out of which 2 µL were taken out for each time point and 
incubated for 3 mins at RT. Ammonium acetate buffer (10 mM) in H2O (pH 7.1) (for the 
m0 control) or in D2O (pD 7.4) was then added to a final volume of 20 µL to initiate the 
H/D exchange. Samples were quenched at varying time points by injection into the LC 
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lines that had been equilibrated with 0.1 % formic acid and kept on ice. A quick gradient 
of 0.1% aqueous formic acid/0.1% formic acid in acetonitrile was immediately ran 
through the column at a constant flow rate of 200 µL/min but was initially disconnected 
from the MS instrument until after 3 mins of the total run has elapsed to allow salt 
removal. The LC line was then connected and ESI-MS data was acquired in positive 
mode using the QStar XL quadrupole TOF-MS fitted with a TurboIon spray source. 
 To account for the back-exchange during data acquisition, a non-deuterated 
control (m0) and a full-deuterated control (m100) were obtained. The full-deuterated 
control was prepared by incubation of the protein in D2O at 37°C for 16 hours and then 5 
minutes at 90°C prior to injection. The relative deuterium uptake (D) was calculated 
using the equation below[8]: 
𝐃 =    (𝒎𝒐𝒃𝒔  !  𝒎𝟎)
(𝒎𝟏𝟎𝟎!  𝒎𝟎)
                              Equation 3.2  
The data points were fitted to a tri-exponential equation where y0 is the actual number of 
exchangeable amide protons at a given condition (%D multiplied by N where N is the 
theoretical number of exchangeable amide protons; N = total amino acid residues – Pro 
residues – 1 for the N-terminus; for FIH-1, N = 324), A, B, and C correspond to the slow, 
medium and fast exchangers with assigned average rate constants k1 (0.05 min-1),  
k2  (1 min-1), and k3 (20 min-1) respectively[36]: 
   𝑦   =   𝑦! − 𝐴𝑒!!!! − 𝐵𝑒!!!! − 𝐶𝑒!!!!  Equation 3.3 
 
3.2.7 Limited Proteolysis with Mass Spectrometry 
 Proteolysis experiments were carried out at 37°C with 150 µg FIH-1 in 50 mM 
Tris pH 7.5 in the presence or absence of 100 µM MnSO4 and 500 µM αKG. Samples 
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were initially incubated on ice for 10 mins and then at 37°C for a minute prior to addition 
of 0.5 mg/mL trypsin to a protease/substrate weight ratio of 1:300. Nine microliter 
aliquots were quenched at varying time points into 1 µL of 10 mM AEBSF and stored at  
-80°C until use. The samples were analyzed as soon as possible. For SDS-PAGE analysis 
in 12% gel, 1.5 µL of the quenched sample was mixed with 6 µL 2X gel loading buffer 
(GLB) and diluted to a total volume of 10 µL with 50 mM Tris pH 7.5. For MALDI-MS 
analysis, 3 µL of the quenched sample was mixed with 15 µL of 10 mg/mL sinapinic acid 
in 70% CH3CN/0.03% TFA. To verify the protein terminal sequence using MALDI in 
source decay, the samples were mixed in a 1:1 ratio with 10 mg/mL sinapinic acid in 
30% CH3CN/0.1% TFA. The air-dried spotted samples were briefly rinsed with cold 
water to remove excess salt and then air-dried again before analysis. MS Data was 
acquired with Bruker Microflex (Billerica, MA) using at least 50% laser power and 5% 
frequency in linear mode. 
3.2.8 Circular Dichroism Spectroscopy 
Protein samples for CD measurements were prepared in 10 mM KH2PO4 (pH 
7.04) with 500 µM αKG and 50 µM MnSO4. Protein concentrations used ranged from 
0.2-0.4 mg mL-1 as measured by UV absorbance at 280 nm (ε280 = 1.22 mL mg-1cm-1). 
The spectra were collected over the wavelength range of 190-250 nm at 37°C using a 
high-transparency quartz cell with pathlength of 0.1 cm on a Jasco J-1500 CD 
spectrometer. The instrument was blanked with the buffer solution containing all 
constituents except the protein. All measurements were collected at least three times to 
ensure that the signal is for that of a sample at equilibrium. The average of these 
measurements were taken and used to generate the CD spectra. 
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3.2.9 Determination of Solvent –Accessible Surface Area (SASA) 
        Solvent accessibility was calculated using the online open software 
GETAREA[39]. The PDB structures 1H2L and 1IZ3 were used for the αKG-bound and 
apo FIH-1 respectively. A water probe radius of 1.4 angstroms was selected for all 
calculations. The values for each amino acid were expressed in % ratios, which represent 
the relative side-chain area to “random coil” value per residue. The “random coil” value 
is assigned as the average SASA of each residue represented as X in the tripeptide Gly-
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3.3 Results and Discussion  
3.3.1 Intrinsic Fluorescence Quenching Indicates αKG-induced Structural Changes in   
FIH-1 
The significant reduction in the intrinsic fluorescence intensity of αKG-bound 
FIH-1 as initially observed in our lab (Figure 3.1) led us to further investigate the effect 
of αKG binding on the enzyme structure, because this is a clear indication that some  
 
Figure 3.1 Trp fluorescence emission spectra of FIH-1 in the absence and presence of 
αKG. Samples contained one or two or all of the following components: 2 µM FIH-1,  
50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment 
was done in duplicate. 
 
 
conformational changes are occurring in the enzyme, at least within the vicinity of the 
reporter Trp residues.  The intrinsic protein fluorescence is predominantly due to 
tryptophan (Trp) emissions, the emission wavelength of which varies from 300 to 350 nm 
depending on the polarity of the protein environment. Hence, Trp fluorescence is a good 
probe for protein structural changes.[41] Intrinsic protein fluorescence quenching 
experiments are commonly employed in our lab to monitor ligand binding to FIH-1. The 
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isosteric Mn+2 was used to replace Fe+2 for all the experiments except the activity assays 
to prevent complicating reactions due to αKG oxidation. The divalent metal cations are 
chemically similar in terms of their preference for the same coordination environment but 
Mn+2 does not support FIH-1 activity[27]. CoCl2 is often used to replace the active site 
metal in Trp quenching assays but in this particular study, MnSO4 was used instead to 
ensure consistency all throughout. The protein concentrations were maintained constant 
during the titration process. 
FIH-1 has eight Trp flourophores and several of them are in the vicinity of the 
active site (Figure 3.2). Binding of Mn2+ only induced a slight decrease in the 
fluorescence intensity as seen in Figure 3.1. This can be attributed to minor 
reorganizations within the active site upon metal binding, which slightly modified the 
surroundings of the reporter Trp. The most likely residue responsible for the fluorescence 
 
 
Figure 3.2 FIH-1dimer structure (1H2L) with the eight Trp residues indicated in black 
sticks. Encircled in red are the Trp residues that most likely contribute to the quenching 
effect seen in the presence of αKG. Trp296 is identified. The cupin barrel core of the 
enzyme is shaded in violet for both monomer units while the red sphere near Trp296 
represents Fe(II) in the active site. 
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signal is Trp296 as it is closest to the metal binding site. The crystal structures revealed a 
very slight movement for this residue as well as the rest of the tryptophans in the 
presence of metal. Upon addition of αKG, the fluorescence signal was significantly 
quenched to more than half of the original intensity implying substantial conformational 
changes within the environment of the Trp residues[35]. The emission maximum appears 
to be slightly blue-shifted in the presence of αKG, which may indicate that the reporter 
tryptophan residues became buried during these structural changes[35]. A close inspection 
of the structures[6,47] revealed that, in the presence of αKG, the indole sidechain of Trp296 
is flipped about the Cβ-Cγ bond such that the indole nitrogen was positioned away – from 
5Å to 7Å, relative to Fe(II). This could possibly account for most of the quenching effect 
observed. A few of the Trp residues are found to be within a sulfur-bearing amino acid, 
which was shown to be an effective quencher of Trp fluorescence[41]. For example, Trp27 
is within 11 Å of Cys216 while a methionine residue (Met275) is within 7 Å of Trp179. 
Several of the Trp residues are found to be within the acidic side chains of Asp and Glu, 
which were also shown to quench Trp fluorescence[41]. Trp76 is within 4Å of Asp161 while 
Trp277 is about 5Å away from the carboxylate of Glu60. There were no observed changes 
in the proximity of the reporter and “quencher” residues upon αKG binding based on the 
available crystal structures. However, this does not completely rule out the likely 
contributions of one or several of the residues mentioned to the observed quenching 
effect. The preliminary fluorescence data clearly implies that some structural changes are 
happening to the enzyme in the presence of αKG. 
To test whether the observed fluorescence results are due to changes in the 
secondary structures of FIH-1 upon αKG binding, circular dichroism spectra of the apo, 
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metal-bound and αKG-bound enzyme forms were obtained at pH 7.11. The spectra as 
shown in Figure 3.3 has two negative features at around 210 nm and 219 nm and a 
positive feature at 191 nm, which is indicative of a mixed α-helix/β-strand structure 
known for FIH-1. The data plainly shows that the structural changes implied by the 
fluorescence data is not due to some large-scale perturbations in the secondary structures 
of FIH-1.  
 
Figure 3.3 Far-UV CD spectra of wild type FIH-1 with and without cofactors. Samples 
contained 50 µM MnSO4, 500 µM αKG and 0.2-0.4 mg/mL enzyme in 10 mM KH2PO4 
pH 7.11 and were analyzed at 37°C. The experiment was done in duplicate. 
 
 
3.3.2 Thermal Stability and Solvent Accessibility Supports αKG-induced Structural 
Changes in FIH-1 
Binding of αKG to FIH-1 could conceivably affect the structural flexibility of the 
enzyme core and so to probe for this effect, we determined the susceptibility of the 
protein to thermal denaturation and solvent exchange. Protein stability in the presence of 
the cofactor αKG was determined by thermal shift assays using RT-PCR.  This assay is 
	   52	  
based on the increase of fluorescence intensity of the hydrophobic dye SYPRO Orange 




Figure 3.4 Thermal shift curves showing the effect of αKG on the thermal stability of 
FIH-1. The inset is the derivative plot to facilitate apparent melting point determination. 
The thermal shift of the assay mix containing one or two or all of the components: 5 µM 
FIH-1, 50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0, was monitored using 
SYPRO Orange dye with an RT-PCR machine. The experiment was done in triplicate. 
 
 
The method utilizes the melt as well as the real-time detection capabilities of RT-PCR 
machines. Addition of metal to apo FIH-1 did not significantly changed the thermal melt 
curve whereas addition of αKG increased the apparent melting temperature from 47°C to 
52°C (Figure 3.4).  This 5°C increase in the enzyme’s thermal stability tells two things – 
(1) that αKG is bound to the active site metal and more importantly, (2) that αKG 
addition resulted in a more tightly folded structure of the protein. A strikingly similar 
observation of the stabilizing effect of αKG was also seen for the other HIF hydroxylase, 
PHD2, using NMR[10] and mass spectrometry[9,36]. 
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The notion of a more rigid FIH-1 structure upon αKG binding is further supported 
by the data from global hydrogen/deuterium exchange experiments coupled to 
mass spectrometry (HDX-MS) (Figure 3.5), which indicate that αKG-bound FIH-1 had 
less solvent-accessible regions than the apo or metal-bound forms of the enzyme as seen 
by the decreased deuterium uptake of the former. A similar observation using the same 
experiment was also noted in our lab for the other HIF hydroxylase, PHD2[36]. The fitted 
parameters summarized in Table 3.1 clearly show the decrease in the total number of 
actual exchangeable sites (y0) in the enzyme upon αKG binding, which implies that 
certain residues became inaccessible.  
 
 
Figure 3.5 Global deuterium uptake plots showing the effect of αKG on the backbone 
amide solvent accessibility of FIH-1. The data were fitted to a tri-exponential equation 
(equation 3.3) (see Table 3.1 below for the summary of the fitted parameters). H/D 
exchange was initiated by diluting samples in 10 mM ammonium acetate buffer pD 7.4 to 
give a final concentration of 20 µM FIH-1, 50 µM MnSO4 and 500 µM αKG. Samples 
were quenched at various time points upon injection into the C4 column equilibrated with 
0.1% formic acid at ~0°C and then analyzed using ESI/TOF mass spectrometry. The 
HDX experiments were done in duplicate. 
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Table 3.1 Summary of the fitted parameters y0 (total exchangers), A (slow exchangers), B 
(medium exchangers), and C (fast exchangers) generated upon non-linear regression 











aThe corresponding average rate constants were fixed accordingly during the fitting: k1 
(0.05 min-1), k2 (1 min-1), and k3  (20 min-1)[36]. The initial parameters obtained were 
relative values; the number of exchangeable amides reported above was calculated by 
multiplying the relative values by N (N = 324). 
bErrors are associated with the derivation of the parameters using equation 3.3. 
 
Because αKG binds to the metal within the enzyme core, the observed solvent 
protection is likely not due to some covered binding interface but rather due to residues 
that became buried upon rigidification of the enzyme. In H/D exchange, a more 
structured protein will exchange with the solvent less frequently due to fewer solvent-
exposed sites and thus will exhibit less deuterium uptake. The results imply then that the 
αKG-bound form of the enzyme is a more compact protein, which is consistent with the 
observed greater thermal stability of this enzyme species. 
 
 
 Apo FIH-1a, b (Mn)FIH-1a, b (Mn+αKG)FIH-1a, b 
y0 186 ± 1 199 ± 5 157 ± 2 
Aslow 47 ± 2 60 ± 8 55 ± 4 
Bmedium 55 ± 3 50 ± 11 51 ± 6 
Cfast 84 ± 3 89 ± 10 51 ± 6 
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3.3.3 αKG Binding Stabilizes the FIH-1 Cupin Barrel Core Against Trypsin Degradation   
To obtain structural insight into the observed αKG-induced conformational 
changes in FIH-1, limited proteolysis coupled to MALDI-TOF mass spectrometry was 
performed. This technique (without gel electrophoresis) has been successfully used to 
monitor the protein-ligand interactions of the related enzyme PHD2 with αKG and αKG 
mimics[15]. Limited proteolysis is widely used for studies of protein dynamics and it relies 
on the fact that exposed regions of the proteins are more prone to proteolytic  
degradation[16]. Conformational changes induced by ligand binding causes certain regions 
of the protein to open up and be more solvent accessible which affects the rate and/or 
nature of proteolysis[16]. In our experiments, trypsin was used as the protease because its 
high specificity (cleavage at the carboxy side of Arg and Lys residues) will enable us to 
predict the potential cleavage sites in FIH-1. This will facilitate downstream 
identification of the generated proteolytic fragments, which will in turn give further 
structural information about the protein regions that were stabilized upon αKG binding. 
Trypsin reactions are typically supplemented with Ca2+ but in our experiments, it was left 
out to prevent precipitation issues, which was observed in our initial studies. All samples 
were quenched in a 1 mM solution of the broad-spectrum serine protease inhibitor 
AEBSF to ensure stoppage of the trypsin reaction as well as to allow for parallel analysis 
of samples using SDS-PAGE and MALDI/TOF-MS. 
The SDS-PAGE data (Figures 3.6A and B) revealed immediate cleavage of both 
apo and αKG-bound FIH-1 after 2 mins of incubation. A total of four major tryptic bands 
were observed for both enzyme forms. The first band corresponded to the intact protein  
(~41 kDa), which was successively degraded as the proteolysis reaction progressed. 
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Figure 3.6 Limited proteolysis of FIH-1 in the absence and presence of αKG as analyzed 
via SDS-PAGE. N stands for negative control which is (Mn+αKG)FIH-1 without trypsin 
incubated for 4 hours (240 mins) at 37°C. M stands for MW marker. Samples were 
analyzed in 12% gel. (A) Protein samples (150 µg FIH-1, 100 µM MnSO4, 500 µM αKG 
in 50 mM Tris pH 7.5) were incubated with 0.5 mg/mL trypsin in a 1:300 
protease/substrate ratio for the indicated time points at 37°C and then quenched in 1 mM 
AEBSF. The sample loading volume used was 1 µL per well corresponding to about 2 µg 
of protein. (B) A second replicate sample was performed as in A but the sample loading 
volume used this time was 3 µL to make band 2 more visible. (C) A third replicate 
sample was prepared as in A but the incubation time was extended to 24 hours (1440 
mins). Arrow indicates the ~34 kDa fragment assigned as band 4. 
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Trypsin cleavage of the intact apo protein appeared to occur more rapidly compared to 
the αKG-bound FIH-1. For the apo enzyme, a second very faint transient band at ~40 
kDa (band 2) was observed after 5 mins, which rapidly disappeared just around 30 mins. 
Figure 3.6B shows the same experiment (but performed on a different day) with three 
times the loading volume to make this particular band more visible.  A third ~ 36 kDa 
fragment (band 3) appeared just after 2 mins of proteolysis and remained until after 30 
mins when it began to diminish and became barely detectable after 4 hours (240 mins). 
Although the band 3 species eventually got cleaved after longer periods of incubation, 
this fragment is the most prominent band for the proteolysis reaction with apo enzyme. A 
slightly less prominent fourth ~34 kDa band (band 4) simultaneously appeared at the 15-
min time point which intensified with time but then became less visible after 4 hours and 
was completely degraded upon prolonged incubation (1440 mins or 24 hours) as shown 
in Figure 3.6C. The band 4 fragment was initially assigned as the stable enzyme core 
species on the basis of it being the only observable band after longer periods of 
incubation (at least 240 mins or 4 hours) for both apo and αKG-bound FIH-1.  
Protein fragments of similar sizes were also generated for the αKG-bound 
enzyme upon trypsinolysis. Although the fragmentation patterns were similar as seen in 
Figure 3.6A, the rates of protein cleavage were clearly different. Firstly, the αKG-bound 
intact protein (band 1) was not as rapidly cleaved as the apo one. Secondly, a more 
visible ~40 kDa fragment (band 2) was observed to appear after 2 mins, which though 
vague at first eventually intensified and then got cleaved after an hour whereas in the apo 
enzyme this fragment is barely visible and was rapidly cleaved after a few minutes. 
Thirdly, the ~36 kDa band (band 3) which also appeared after 2 mins was cleaved after 
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just an hour of incubation unlike in the apo enzyme where band 3 is still detectable up to 
4 hours. It seems that addition of αKG accelerated the trypsin cleavage of this particular 
fragment. Lastly, the rate of proteolysis of the ~34 kDa fragment (band 4) which was 
previously assigned as the stable core decreased significantly in the presence of αKG.  In 
fact, the intensity of this core fragment remained strong after 4 hours and was still intact 
even after 24 hours of proteolytic treatment whereas it completely disappeared for the 
apo enzyme under longer incubation periods (Figure 3.6C).  
To summarize the gel results, it was found that for the αKG-bound enzyme (i) the 
intact ~41 kDa protein (band 1) was more resistant to trypsin degradation, (ii) the ~40 
kDa fragment (band 2) which appeared after 2 mins was more intense and slightly more 
resistant to degradation, (iii) the ~36 kDa fragment (band 3) which also appeared after 2 
mins was more rapidly degraded and (iv) the ~34 kDa core fragment (band 4) which 
appeared after 15 mins was much more intense and much more resistant to trypsin 
degradation. Together, the limited proteolysis data implicates the generation of a more 
stable and more structured protein core in the presence of αKG, which is consistent with 
the previous thermal shift and H/D exchange data.  
To gain further structural insight on the effect of αKG on FIH-1 flexibility, 
parallel analyses of the same samples used for electrophoresis were performed using 
MALDI-TOF mass spectrometry. The MS data (Figure 3.7 and Table 3.2) largely 
corroborated the gel results for the αKG-bound enzyme but not so much for the apo 
form. For example, the gel data indicates that the intact enzyme (band 1) is mostly 
cleaved after 30 mins whereas it is still clearly present based on the MS data. This may be  
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Figure 3.7 Analysis of the limited proteolysis data of FIH-1 by MALDI/TOF mass 
spectrometry in linear mode. The same quenched samples (150 µg FIH-1, 100 µM 
MnSO4, 500 µM αKG in 50 mM Tris pH 7.5) used in SDS-PAGE analysis were mixed 





Table 3.2 Summary of the average observed masses for the four major tryptic fragments 
determined after MALDI/TOF-MS analysis.  
 
 
Protein Species Observed MWa Calculated MWb 
Band 1 (intact FIH-1) 41186 ± 635 40567 
Band 2 39601 ± 489 40076/38728 
Band 3 36654 ± 585 36349/36178 
Band 4 34904 ± 609 34931/34897 
a The errors represent the FWHM values generated after fitting the peaks to a Gaussian 
function. 
b The calculated MW are the masses of FIH-1 trypsin fragments that are consistent with 
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partly attributed to sample loading errors. The transient, least intense band 2 species 
corresponding to the ~40 kDa fragment was barely detected by MALDI under the 
conditions used for apo enzyme but the rest of the gel bands were accounted for. 
In an effort to identify the observed trypsin fragments, the FIH-1 amino acid 
sequence together with the crystal structure was manually inspected for the solvent- 
exposed Arg and Lys residues. The solvent-accessible surface areas (SASA) of these 
basic residues were also calculated for both apo and αKG-bound FIH-1 using the 
respective crystal structures (1IZ3 and 1H2L). Residues with SASA ratio values greater 
than 30% are generally considered to be solvent exposed[19]. A simplified diagram of the 
primary structure of FIH-1 (Figure 3.8) was created to illustrate the proposed cleavage 
sites that can possibly account for the observed masses of the protein fragments 
generated. While both termini of FIH-1 revealed potential trypsin cleavage sites upon 
inspection of the structure as well as from SASA calculations, attention was initially 
focused on those basic residues at the N-terminus because of the involvement of the      
C-terminus in FIH-1 dimerization. All the reactions were done in buffer at physiological 
pH (7.0) and temperature (37°C) so the enzyme is most likely in the dimeric form.  
Notable likely exceptions to this are the C-terminal residues Lys301 and Lys314, which are 
situated within or at the end of a loop excluded from the buried regions of the C-
terminus. Cleavage at any of these residues will generate a ~34 kDa and a ~36 kDa 
fragment respectively (Figure 3.8B). The C-terminal residue Lys348 is another potential 
cleavage site, which is located at the end-most exposed region of the dimer interface. 
Cleavage at the carboxyl side of this residue will generate a ~40 kDa fragment. 
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At the N-terminus of FIH-1 are three likely cleavage sites as well – Arg20, Arg43, 
and Arg54. There is a likelihood that the successive trypsin cleavage of the protein at 
these sites, which is dictated by the solvent accessibility of the residues, is responsible for 
the observed trypsin fragmentation pattern. Using the simplified diagram in Figure 3.8B, 




Figure 3.8 (A) Primary structure of FIH-1 showing all the possible predicted trypsin 
cleavage sites located at the carboxyl side of basic amino acids marked in red. 
Highlighted in grey are the amino acids involved in the enzyme dimer interface. (B) 
Diagram of intact FIH-1 showing the likely cleavage sites upon trypsin digestion. The 
molecular masses of the resultant trypsin fragments are shown. Only those sites with 
calculated SASA values exceeding 30% and whose predicted fragment masses 
corroborates with the available limited proteolysis data are shown.  
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generates a ~39 kDa fragment will give rise to band 2 in the gel, (ii) a second cleavage at 
Arg43 which generates a ~36 kDa fragment will give rise to band 3 and (iii) a third 
cleavage at Arg54 which generates a ~34 kDa fragment will give rise to band 4. However, 
analysis of the actual masses of the four major protein fragments by MALDI/TOF-MS, 
which are summarized in Table 3.2, revealed that the predicted mass upon cleavage at the 
carboxyl side of Arg20 (MW = 38728) is not within the error of the observed mass for the 
band 2 species. On the other hand, the predicted fragment mass for that of the C-terminal 
residue Lys348 (MW = 40076) is within the error and might therefore likely account for 
the observed mass. Using a similar argument, the band 3 species can be satisfactorily 
accounted for either by cleavage of intact FIH-1 at the N-terminal residue Arg43 (MW = 
36178) or at the C-terminal residue Lys314  (MW = 36349). Notably, Lys314 residue is 
located at the beginning of the helix region of the enzyme dimer interface so the 
probability of cleavage relative to Arg43 is lower, though the possibility cannot be entirely 
ruled out. Similarly, the band 4 species can also be accounted for either by cleavage of 
intact FIH-1 at the N-terminal residue Arg54 (MW = 34931) or at the C-terminal residue 
Lys301 (MW = 34897). 
As mentioned previously, band 4 (~34 kDa fragment) was initially assigned as the 
stable enzyme core species due to the observed stability of this fragment during trypsin 
degradation.  To support this assignment as well as to identify the actual protein fragment 
of band 4, sequencing data was obtained via in-source decay (ISD) using MALDI-TOF 
mass spectrometry (Figure 3.9). MALDI-ISD is a useful tool for top-down sequencing to 
verify the end termini of intact known proteins[29,30]. The fragmentation process during 
ISD occurs via a radical pathway and so the major fragment ions expected to form 
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Figure 3.9 Top-down sequence verification of the ~34 kDa tryptic fragment (band 4) of 
FIH-1 using in-source decay (ISD) coupled to MALDI/TOF-MS. The sample quenched 
after 4 hours of protease incubation was used for the analysis. It was mixed with 10 
mg/mL sinapinic acid in 30% CH3CN/0.1% TFA in a 1:1 ratio. (A) Spectrum showing 
the c-, (zn+2)- and a few y-ions identified for the m/z range lower than 2000. Also shown 
are the verified N- and C-terminal sequences of FIH-1. (B) Spectrum for the m/z range 
higher than 2000.  
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Table 3.3 Summary of the observed c- and z-ions for the 34 kDa fragment (band 4) 
generated during ISD-MALDI/TOF-MS. The regions of the N- and C-termini identified 

















V 1270 1271 G 2028 2028 
V 1369 1370 N 1915 1915 
L 1484 1483 P 1819 1818 
T -- 1584 Q 1689 1689 
D -- 1699 E -- 1560 
T 1799 1800 V 1461 1461 
N 1915 1914 G -- 1404 















K 2699 2698 N 3186 3185 
W 2885 2884 I 3070 3071 
D 3001 3000 E 2959 2958 
L -- 3113 K -- 2828 
E 3242 3242 M 2701 2700 
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are the cn and (zn+2) ions[31]. Peaks corresponding to the ladder of (zn+2)-ions as well as 
some c-ions generated at 60% laser power were observed and identified for the parallel 
sample ((Mn+αKG)FIH-1) quenched after 4 hours of trypsin incubation. This particular 
sample was chosen based on SDS-PAGE and MS results which showed that the dominant 
protein species present at the specified timepoint is the ~34 kDa fragment (Figures 3.6 
and 3.7). A few y-ions were also observed, which is unusual but not impossible[29,31]. The 
identified fragment ions were summarized in Table 3.3. This analysis verified parts of the 
N-terminal sequence of the fragment. More importantly, parts of the C-terminal sequence 
involved in FIH-1 dimerization were also identified, ruling out the cleavage at the C-
terminal residue Lys301 (MW = 34897) as the event that generated band 4. The sequence 
data unambiguously identified the band 4 species as the protein fragment generated upon 
trypsin cleavage at the N-terminal residue Arg54 (MW = 34931). 
The observed difference in the rates of trypsin proteolysis for apo versus αKG-
bound FIH-1 is consistent with the idea of the existence of at least two distinct 
conformational states of the enzyme, which is dependent on the cofactor present. Each 
enzyme form conceivably represents a different conformational state. 
3.3.4 αKG Binding is a Prerequisite for Optimal HIF-1α/CTAD Substrate Binding  
 Based on early observations mentioned previously that imply the requirement of 
cofactors for sufficient HIF-1α/CTAD binding[32,33], we further postulated that the 
substrate only binds optimally to the αKG-bound form of the enzyme. To initially test 
this hypothesis, we turned again to intrinsic fluorescence quenching experiments. As with 
the previous Trp quenching experiments, the protein concentrations were kept constant 
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all throughout.  Addition of HIF-1α/CTAD substrate to apo or metal-bound FIH-1 did 
not cause a significant change in the quenching intensity (as indicated by the filled data 
points in Figure 3.10) implying that either the substrate did not bind the enzyme or its 
binding did not drastically perturb the environment of the reporter tryptophan residues. 
The former case is the most likely event, i.e. the substrate did not bind, because upon 
addition of HIF-1α/CTAD to the αKG-bound form of the enzyme, the signal was 
quenched to some extent, which was taken as an indication of a binding process. The  
 
Figure 3.10 Trp fluorescence emission spectra of FIH-1 in the presence of HIF-1α/ 
CTAD substrate. Samples contained one or two or all of the following components: 2 µM 
FIH-1, 50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). Empty 
data points – spectra in the absence of CTAD; filled data points – spectra in the presence 
of 200 µM HIF-1α/CTAD. 
 
 
preliminary data suggests that optimal HIF-1α/CTAD binding requires the prior presence 
of αKG in the active site of FIH-1. This will support the sequential ordered binding 
mechanism proposed for this enzyme[19]. Inspection of the structures with bound substrate 
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showed sidechain reorientations of two Trp residues, Trp27 and Trp296, which possibly 
accounts for the observed quenching effect. Altogether, the available data suggest that, 
despite the lack of crystallographic evidence, FIH-1 undergoes substantial structural 
changes prior to HIF-1α/CTAD binding, which are very likely relevant to the enzyme’s 
hydroxylase function. The conformational perturbations possibly occur on a binding or 
catalytic timescale.  
To lend more experimental support to the proposed model that HIF-1α/CTAD 
only binds optimally to αKG-bound FIH-1, preliminary binding experiments were 
performed by monitoring the changes in the intrinsic protein fluorescence intensity upon 
substrate addition. Figure 3.11 shows HIF-1α/CTAD binding data obtained for FIH-1 in 
the presence and absence of αKG. One can deduce from the data that the substrate 
apparently does not even bind when αKG is absent or if it does, binds with an extremely 
low affinity that cannot be determined from the available data points and possibly in a 
different non-optimal binding orientation as a trend of slight fluorescence enhancement 
was generally observed instead of fluorescence quenching (supplemental Figure 3.16). 
On the other hand, it clearly binds when αKG is present as seen in Figure 3.11. Nonlinear 
curve-fitting of the plot for the αKG-bound FIH-1 gave a KD value of 92 ± 9 µM which 
is well within the range of the KD, CTAD values (~90 µM) for FIH-1 previously observed 
(supplemental Figure 3.17) in our lab as well as the reported KM, CTAD (~79 µM)[5]. The 
results clearly indicate that the affinity of the substrate depends on the cofactor bound to 
FIH-1, suggesting distinct conformational states for the apo/metal- and αKG-bound 
enzyme forms. 
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Figure 3.11 Binding of HIF-1α/ CTAD substrate to FIH-1 in the absence ((Mn)FIH-1: 
open circles, apo FIH-1: filled triangles) and presence (filled circles) of αKG. Samples 
contained one or two or all of the following components: 2 µM FIH-1, 50 µM MnSO4, 
500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment was performed 
in duplicate at an excitation λ of 295 nm and the intrinsic fluorescence quenching was 
monitored between 300 to 375 nm.  Nonlinear regression analysis of the plot for the 
αKG-bound enzyme using equation 3.1 gave a KD value of 92 ± 9 µM.  
 
3.3.5 αKG-induced Conformational Changes in FIH-1: Implications for Substrate 
Binding, Product Release, Regulation and Selective Inhibition of FIH-1 
The available results clearly demonstrated that the ternary metal-αKG/FIH-1 
complex assumes a more compact structure, which rendered FIH-1 more resistant to 
thermal denaturation, deuterium exchange and protease attack compared to apo enzyme. 
These are clear indications of a conformational change induced by αKG despite the 
absence of crystallographic evidence.  In light of this, the B-factors were analyzed using 
the available crystal structures. As shown in Figure 3.12, the outer rims of the enzyme 
barrel core consisting of alpha-helices and loops were mostly flexible in the absence of 
	   69	  
αKG. The presence of these flexible regions in the apo enzyme indicates a more loosely 
structured protein, which is consistent with the observed greater susceptibility of the apo 
form of FIH-1 to thermal denaturation, deuterium exchange, and protease attack. As 
demonstrated by the available thermal stability and solvent exchange data, the presence 
 
 
Figure 3.12 Comparison of the B-factors mapped onto the 3-D surface for apo (1IZ3) 
and αKG-bound (1H2N) FIH-1.  
 
 
of the metal did not significantly changed the profile of the enzyme relative to the apo 
form indicating that metal-bound FIH-1 exhibited a similar open structure as apo FIH-1. 
On the other hand, the presence of αKG induced conformational changes that rendered 
the enzyme more thermally stable and less accessible to solvent as well as protease 
attack, which is indicative of a more tightly structured protein.   
The binding of αKG to FIH-1 greatly stabilized the enzyme core (~34 kDa 
protein fragment corresponding to band 4 in the gel), which was shown to comprise the 
eight-stranded β-barrel (or cupin barrel) without the enzyme region opposite the substrate 
binding site (shaded in green in Figure 3.13). This conclusion was based on the available 
limited proteolysis data coupled to mass spectrometry and MALDI-ISD sequencing data. 
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The observed substantial stabilization of αKG-bound FIH-1 jives very well with the 
molecular dynamics results of an earlier study[53]. 
The cupin barrel core is conserved among the αKG-dependent oxygenase 
superfamily[24]. It serves as a common platform where the active site pocket is enclosed 
and where a combination of loops, alpha helices and additional beta strands extends out 
from the core to form the substrate contacts unique for each enzyme[5]. It can be seen in 
Figure 3.13 that removal of the protein region, which gets cleaved off by trypsin (shaded  
 
 
Figure 3.13 (A) FIH-1 primary structure showing the trypsin cleavage at Arg54 (indicated 
by the arrow) to generate the 34 kDa core monomer fragment. Shaded in green is the 
protein region that gets cleaved off from the enzyme core species. (B) Front and flipped 
backside view of FIH-1 dimer structure showing the location of the green region. The 
cupin barrel core is shaded in purple. The red sphere is Fe(II) in the active site. 
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in green) to generate the ~34 kDa species, will still leave the active site within the barrel 
core as well as the dimer interface intact. We predict then that the ~34 kDa protein 
fragment should still exhibit residual hydroxylation activity. 
The available data allowed for the conception of a simple equilibrium model 
(Figure 3.14) for FIH-1. The salient features of the model are as follows: (1) the enzyme 
dimer exists in at least two conformational states: the loose, more flexible state and the 
tight, more stable state, (2) the population of each conformational state depends on the 
presence of cofactors, (3) the tight, more stable conformer represented by the αKG-
bound enzyme species is more suited for optimal substrate binding (Scheme 3.1). The 
cupin barrel core of FIH-1 allowed for a more compact restructuring of the enzyme in the 
presence of cofactors. 
 
 
Figure 3.14 Proposed model for the different conformational states of FIH-1. The 
population of these states depends on the presence of cofactors. Binding of the metal to 
apo enzyme does not induce significant structural changes whereas binding of αKG to 
the metal-bound form of the enzyme induces stabilizing changes within the active site 
core that results to pre-formation of the substrate-binding site.  
 
 
The observed structural changes in the presence of αKG are likely connected with 
the subsequent step, which is substrate binding. These changes are possibly localized in 
the vicinity of the active site within the cupin barrel core but do not involve major 
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perturbations in the secondary structures as supported by CD spectroscopy. Rather, the 
changes likely involve the “inward packing” of the cupin barrel core itself, which resulted 
in the “clamping” together of mobile elements protruding out of the core to better define 
the substrate-binding site. The proposed changes are conceivable given that αKG 
interacts with both sides of the β-barrel when coordinated to the metal center. On one side 
of the barrel are the residues Asn205 and Asn294, which form H-bond interactions with the 
C1 carboxylate of αKG; while on the other side of the barrel are the residues Lys214 and 
Thr196, which form interactions at the C5 carboxylate end. One can imagine the inward 
pulling effect that the enzyme core experiences upon αKG binding resulting to FIH-1 
stabilization as consistently implied by the available data. Since the conformational 
changes are proposed to involve the same structural elements that just got packed tighter, 
such subtle structural information will have been lost in the ensemble-averaged view of 
crystal structures. Thus, quite ironically, the proposed inward packing model can also 
potentially explain the observed lack of crystallographic evidence for the proposed αKG-
induced structural changes. This is in contrast with CurA, an enzyme from the same 
superfamily, which was shown via crystallography to have distinct αKG-dependent open 
and closed conformations[59]. 
The idea of a more rigid, stable structure for priming the enzyme towards optimal 
substrate binding seems counterintuitive if the induced-fit model is invoked[28,34]. 
However, as implied before, it can also mean that the more rigid protein core allowed for 
the flexible elements to come together to properly pre-define the substrate-binding 
groove. The induced-fit model still applies for FIH-1 as further sidechain reorientations 
are clearly happening upon the actual substrate binding event based on the crystal 
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structures[7].   A pre-formed substrate binding site would make sense for FIH-1 given that 
(1) the HIF-1α/CTAD substrate is mostly unstructured in solution prior to binding[54] and 
that (2) the substrate can adopt different structures when bound depending on the nature 
of the binding partner[7,54] (Figure 3.15). For example, when bound to FIH-1, the crystal 
structures revealed two sites of interaction for HIF-1α/CTAD substrate: site 1 or the 
hydroxylation site (-LTSYDCEVN803API-) in which the susbstrate is mostly in the coil 
conformation extending to a single tight turn that projects the target Asn803 residue into 
the active site pocket and, site 2 or the C-terminal site (-LQGEELLRAL-) in which the 
substrate adopts a short helical structure[7]. A manual inspection of the tight turn formed 
by the FIH-1-bound substrate revealed that it is an inverse γ-turn consisting of three site 1 
residues (-VN803A-) and which have an H-bond formed between the backbone carbonyl 
oxygen of Val802 residue and the amide group of Ala804 residue. On the other hand, when 
HIF-1α/CTAD is bound to the trans-coactivator p300/CBP, the same two sites of 
interactions were also observed but parts of the site 1 region (-SYDCEVN803-) was  
 
Figure 3.15 Different conformations adopted by 788-826 HIF-1α/CTAD depending on 
its binding status. Highlighted in gray are the two sites of interaction. The target Asn803 
residue is located on site 1. The straight line indicates unstructured coil conformation. 
Also indicated is the tight γ-turn (spanning -VN803A- residues) formed upon binding to 
FIH-1.   
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shown to adopt a helical structure instead of the extended coil conformation. One can 
imagine then how a pre-formed binding site will allow for the selection of a particular 
binding orientation that will be optimal for the ensuing molecular process. The relatively 
more polar environment of the FIH-1 binding site interacting with site 1 of HIF-1α/ 
CTAD substrate favored the formation of the inverse γ-turn. This binding environment 
does not require as much enthalpic stabilization as when the binding site is mostly 
hydrophobic like in the case of p300/CBP[54] wherein the hydrophobic interactions can be 
energetically satisfied by the more extensive intrapeptide H-bonding in an α-helix.  The 
entropic penalty that must be paid to form the critical γ-turn upon binding to FIH-1 is 
more than compensated by the observed enzyme stabilization of αKG-bound FIH-1 as 
well as the intraturn H-bond formed and the favorable substrate interactions that lock the 
target HIF-1α/CTAD-Asn803 in place. The pre-formed binding site also limits the 
conformational space of the substrate and thus, selectively favors the optimal binding of 
HIF-1α/CTAD. The absence of a pre-formed binding site can possibly explain the 
observed extremely low affinity of the substrate for the apo or metal-bound enzyme 
forms. This active site feature of FIH-1 is not seen in the other HIF hydroxylase, the 
PHDs, which employ a lid domain in the form of the β2β3 loop to recognize and bind 
substrates[36,55]. Therefore, the unique pre-formed substrate-binding site of FIH-1 in the 
presence of αKG has the potential to become a selective therapeutic target. In fact, an 
early study based on crystal structures of FIH-1 had recognized this precise structural 
constraint of the enzyme as a possible target for future inhibitor design[7]. Perhaps this 
same structural constraint within the active site is the basis for the substrate selectivity of 
FIH-1. One can speculate that any unstructured protein sequences which can form a       
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γ-turn or possibly any tight turn and which contain a properly placed Asn residue or a 
similar-sized one with a β-methylene group are potential substrates.  
Pre-organization of the substrate binding site has been observed by several groups 
for the αKG dioxygenases[11-14], although the significance in the context of the proposed 
sequential binding order was not realized then. Conceivably, the model shown in Figure 
3.14 provides a structural basis for the proposed sequential ordered mechanism of FIH-1. 
The cofactor αKG binds to Fe(II) in the active site, which induces the enzyme to undergo 
structural rearrangements possibly via core packing, resulting in a more stable enzyme 
form that favors optimal substrate binding. Hence, αKG has to necessarily bind first 
before the substrate. Unprecedented support for the proposed model comes from early 
studies that initially established the involvement of FIH-1 to hypoxia sensing[32,33]. 
According to those studies, one implication is that HIF-1α/CTAD does not sufficiently 
bind to FIH-1 unless the cofactors are included. The proposed model satisfactorily 
explained these earlier observations. Only when the cofactors are bound will the proper 
substrate binding site form, allowing HIF-1α/CTAD to assume the inverse γ-turn needed 
to properly project the target residue towards the metal center.  
The available data also allowed for the conception of a mechanistic model 
(Scheme 3.1) consistent with the proposed conformational state model for FIH-1.  
 
Scheme 3.1 Mechanistic model showing the probable basis for the sequential ordered 
mechanism proposed for FIH-1. 
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Productive substrate binding only occurs when both metal and αKG are bound to the 
enzyme. The substrate has a very low affinity for the apo enzyme as supported by the 
binding assays; if ever binding does occur, it can unfavorably block the binding of 
cofactors giving rise to an unproductive enzyme complex. Thus, in order to form a 
productive enzyme complex, the binding of the cofactors has to necessarily happen prior 
to substrate binding. This provides additional mechanistic support for the proposed 
sequential binding mechanism of FIH-1. 
As subtly illustrated in Figure 3.14, the enzyme assumes a more open structure 
without αKG. This can potentially provide a structural mechanism for product release 
whereby the products are released upon equilibrium shift to the more loosely structured 
and therefore more open metal-bound enzyme form, which occurs as αKG is being 
consumed. However, for productive reactions, it becomes necessary that the rate at which 
this proposed shift happens is slower than the rate of coupling between αKG oxidation 
and substrate hydroxylation. 
At the risk of sounding highly speculative, we also realized the potential insight 
that our proposed model might provide regarding FIH-1 regulation. It can, for example, 
provide a mechanistic strategy through which FIH-1 is potentially regulated and readily 
made available when the need arises. Referring to Scheme 3.1, one can imagine that 
binding of a suitable ligand to the apo enzyme under hypoxia can reversibly lock the 
enzyme in a conformational state that is not amenable for productive turnover. This will 
decrease the available pool of enzymes until conditions return to normal, i.e. normoxia, 
whereby the enzyme will be made available again by reversible ligand dissociation. 
Again, we cannot emphasize enough that the idea is highly speculative at this point of the 
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study but it is not too far-fetched and can be further explored to shed light in a critical 
area that is largely unknown for this enzyme superfamily. 
 
3.4 Conclusions and Future Directions 
In this chapter, the effect of αKG binding on the structure of FIH-1 was 
investigated in an effort to explore the subtle differences in the enzyme-substrate 
interactions that might prove useful for future selective therapy. The available data 
allowed for the conception of a simple equilibrium model for FIH-1, wherein the enzyme 
dimer exists in at least two conformational states, the population of which is αKG-
dependent. The binding of αKG shifts the equilibrium towards the more tightly folded 
and stabilized enzyme state as strongly indicated by the results showing the decreased 
susceptibility of αKG-bound FIH-1 to thermal denaturation, solvent exchange and 
protease attack. The stabilization effect of αKG on FIH-1 is likely due to the “inward 
packing” of the cupin barrel core upon formation of interactions with enzyme core 
residues on both sides of the barrel. One way to test the model is to disrupt these 
interactions via single-point mutations of residues shown to interact with αKG on either 
side of the barrel such as Asn205 and Thr196 and to compare the stabilization effect of 
αKG on these variants relative to wildtype FIH-1.  
The more stabilized enzyme state of αKG-bound FIH-1 due to “inward packing” 
is proposed to promote optimal substrate binding via pre-formation of the substrate-
binding site. The available results support this as a greater affinity of the HIF-1α/CTAD 
substrate for the αKG-bound enzyme form was observed. This would be the first time 
such a model was proposed for FIH-1 or for any Fe(II)/αKG-dependent dioxygenase. To 
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be clear, the premises of the model are (1) that FIH-1 exists in at least two 
conformational states, the population of which is αKG-dependent, (2) that αKG binding 
induces stabilizing conformational changes in FIH-1 which leads to pre-formation of the 
optimal substrate binding site and, (3) that stabilization of FIH-1 upon αKG binding as 
well as the intraturn H-bond and the optimal interactions formed upon substrate binding 
more than compensates for the entropic penalty required by HIF-1α/CTAD substrate to 
form the tight γ-turn. For future studies, a more robust binding experiment than the 
intrinsic fluorescence quenching assay will have to be performed in order to provide 
unambiguous support to the notion that the substrate only binds optimally to the αKG-
bound enzyme form. Isothermal titration calorimetry is an ideal tool for this purpose as it 
has the added benefit of providing a complete thermodynamic profile of the binding 
process. However, this method is easier said than done especially for a dimer enzyme like 
FIH-1, which requires cofactors and whose substrate is a potentially sticky peptide. 
For future investigations, computational studies using methods that are based on 
recent MD simulations coupled to computational analyses such as quasi-anharmonic 
analysis (QAA)[60] as well as the traditional quasi-harmonic approximation[61] can be 
done to further probe the proposed conformational states of FIH-1 and their relevance to 
enzyme function. Experimental studies using NMR spectroscopy would be a very useful 
tool to correlate the enzyme conformational dynamics to enzyme function in solution. 
However, the size of the FIH-1 dimer (~80 kDa) as well as the need for huge amounts of 
enzyme and substrate might be serious limitations. An alternative tool that will still allow 
for the study of the enzyme under turnover conditions albeit with lower resolution would 
be small angle x-ray scattering. Unlike NMR though, any structural information obtained 
	   79	  
from this method would have to be coupled to kinetic data obtained from other means to 
enable the correlation of enzyme dynamics to activity. Another useful low-resolution tool 
for this purpose is single molecule fluorescence. It has the added benefit of providing 
information about the different conformational states of the enzyme without requiring 
huge amounts of the protein.  
The model being proposed in this study definitely warrants further rigorous 
testing as it has great potential to provide for several unprecedented insights into the 
nature of substrate binding, product release, and possibly regulation of FIH-1. Equally 
important is the great potential to selectively target FIH-1 via its proposed pre-formed  
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3.5 Appendix 
3.5.1 Abbreviations 
HDX, hydrogen deuterium exchange; 
MALDI, matrix assisted laser desorption ionization; 
NMR, nuclear magnetic resonance; 
TOF, time-of-flight; 
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; 
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3.5.2 Supplemental 
 
3.5.2.1 Binding of HIF-1α/CTAD to different enzyme forms of FIH-1 
         
  
 
Figure 3.16 Representative fluorescence emission spectra of (Mn+αKG)FIH-1, 
(Mn)FIH-1, and apo FIH-1 in the presence of HIF-1α/CTAD substrate. Samples 
contained one or two or all of the following components: 2 µM FIH-1, 50 µM MnSO4, 
500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment was performed 
at an excitation λ of 295 nm and the emission was monitored between 300 to 375 nm. 
The data curves shown were unsmoothed. The arrows show the general trend of change 
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3.5.2.2 Binding of HIF-1α/CTAD to (Co+αKG)FIH-1 
         
 
Figure 3.17 Binding of HIF-1α/CTAD substrate to (Co+αKG)FIH-1. CoCl2 was used to 
replace Fe(II) in the active site. The sample contained 2 µM FIH-1, 25 µM CoCl2, and 
500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment was performed 
in triplicate at an excitation λ of 295 nm and the fluorescence quenching monitored 
between 300 to 375 nm. The inset figure shows a sample of the fluorescence emission 
spectra generated. The trend as shown by the arrow is decreasing intensity with 
increasing amounts of the substrate.  Curve-fitting using equation 3.1 gave a KD value of 
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CHAPTER 4 




A defining characteristic of O2 sensing by the non-heme Fe(II)/αKG-dependent 
dioxygenase, FIH-1, is that O2 activation must occur with high fidelity to transduce the 
signal in the form of hydroxylation at HIF-1α/CTAD-Asn803, requiring the tight coupling 
between HIF-1α substrate binding and O2 activation. How exactly the enzyme performs 
this is yet to be resolved and would potentially provide useful insights about its substrate 
selectivity for selective targeting as well as future enzyme engineering studies. One 
conclusion that is apparent from all the mechanistic studies done for FIH-1[17,22,23,25-27] is 
that, in order to achieve efficient oxygen activation, the native substrate must be able to 
effectively displace the water ligand occupying the sixth coordination site of Fe(II). This 
is part of the so-called substrate triggering mechanism wherein oxygen activation only 
occurs at an appreciable rate when native substrate is present[14,38]. This phenomenon has 
been empirically observed for other members of the nonheme iron dioxygenase 
superfamily such as clavaminate synthase and phenylalanine hydroxylase[17,18,28,29]. While 
there is still no known similar evidence for FIH-1, the very slow reactivity of the enzyme 
with oxygen in the absence of substrate to form the autohydroxylated species[4] is indirect 
support for the substrate-induced O2 activation phenomenon.  
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In the proposed mechanism for FIH-1 (Scheme 1.1), binding of the substrate 
triggers O2 binding to αKG-bound Fe(II). This was proposed to occur via disruption of 
the H-bond interaction between the unbound oxygen of the facial triad carboxylate Asp201 
residue and the axial water ligand, thus facilitating aquo release and creating an empty 
coordination site for O2 binding[14,21-23,27]. The disruption results in a new H-bond 
interaction between Asp201 and the backbone amide of HIF-1α/CTAD-Asn803. Upon 
binding to the vacant coordination site, O2 is subsequently activated to the superoxide 
nucleophile, which can then attack the keto-carbon of αKG to generate succinate, CO2 
and the proposed ferryl (FeIVO) oxidant species. These steps can be thought to comprise 
the first half of the catalytic cycle, which will be referred to as αKG oxidation or 
succinate production. The second half comprises the insertion of oxygen into the 
unactivated beta C-H of HIF-1α/CTAD-Asn803 to produce the hydroxylated substrate, 
which will be referred to as HIF-1α/CTAD hydroxylation. At the point of the cycle 
where the putative ferryl species is formed (i.e. upon succinate production), the reaction 
can be uncoupled, meaning no hydroxylated substrate is produced afterwards. Insofar as 
FIH-1 is concerned, this uncoupling has only been observed in (1) certain enzyme 
variants in the presence of native substrate[16] or (2) wild-type enzyme in the presence of 
poor substrate variants[23,26] but not with wild-type enzyme and native substrate together 
under turnover conditions[5,16]. The mechanism of the observed uncoupling still remains 
to be established though there are strong hints that proper substrate positioning plays a 
key role[16,24]. So far, there is no direct evidence of what exactly happens to the putative 
ferryl species during uncoupling; it is very likely that the reactive species exchanges with 
a solvent molecule[3,4] and subsequently hydroxylates some nearby properly oriented 
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oxidizable residue within the active site. Indeed, our group has shown spectroscopic 
evidence of this event also known as autohydroxylation (or self-hydroxylation)[4]. The 
production of reactive oxygen species (ROS) was ruled out as an alternate route for the 
putative ferryl oxidant in FIH-1 as there was none observed[5].  It becomes apparent then 
that the second half of the catalytic cycle for FIH-1, which results in HIF-1α/CTAD-
Asn803 hydroxylation, will only proceed and thus be coupled to the first half when the 
generated reactive iron oxidant species is sufficiently juxtaposed with the target residue 
of the substrate.  
The exact mechanism by which FIH-1 achieves tight coupling of the first half 
(αKG oxidation) to the second half of the catalytic cycle (HIF-1α/CTAD hydroxylation) 
remains unresolved, although there have been several proposed models[16,24,35]. One 
model, based on spectroscopic studies with the related enzyme clavaminate synthase 2, 
describes the conversion of the coordination geometry of the active site Fe(II) from six-
coordinate (6C) to five-coordinate (5C), which requires the binding of both the 
cosubstrate αKG, and native substrate[35]. The premise is that only upon binding of the 
substrate will the metal coordination switch happen making iron more reactive to O2. 
Hence, dioxygen activation leading to αKG oxidation will only occur once the substrate 
is in proximity, which ensures tight coupling. Support for the model came from 
spectroscopic-based observations of the metal coordination switch noted for the other 
related enzymes[28,29]. While the metal coordination switch model holds true for FIH-1 as 
previously shown by MCD studies[25], it cannot sufficiently account for the observation 
that certain FIH-1 variants, such as the facial triad Asp201 mutants[36] and mutants of 
Gln239 residue[16,31], significantly uncouple even in the presence of the enzyme’s native 
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substrate. Indeed, enhanced αKG oxidation was observed for the Asp201 variants as 
evidenced by the greater [14C]CO2 production compared to wild-type FIH-1[36]. 
Nonetheless, the same study provided mechanistic support to the model as the 
decarboxylation of αKG was observed to be 10-fold lower in the absence of substrate. 
Clearly though, the enzyme employs additional mechanisms to ensure that αKG 
oxidation will efficiently proceed to HIF-1α/CTAD hydroxylation. 
An extension of the earlier model, this time based on data using TauD[24], 
describes the involvement of H-bond interactions between the facial triad carboxylate 
Asp201 and the axial sixth water ligand previously seen in crystal structures[30]. The 
premise is that only upon binding of the native substrate will the H-bond get disrupted, 
which provides the trigger for the release of the last water ligand. Aquo release results to 
conversion of the iron coordination geometry from 6-coordinate to 5-coordinate creating 
a vacant site for O2 binding. Thus, O2 binding and the subsequent activation will only 
occur once the substrate binds, ensuring tight coupling of αKG oxidation to HIF-1α/ 
CTAD hydroxylation. Unlike the earlier model, the aquo ligand release model was able 
to account for the observed uncoupling of the facial triad carboxylate Asp201 mutants[36].  
Our group further postulated a variation of the model, which not only describes the 
involvement of H-bond interactions between the first sphere residues but also between 
residues surrounding the active site like Gln239 and the target Asn803 residue of HIF-1α/ 
CTAD substrate. The presumptions are that (1) the interactions involving the first sphere 
residues facilitate dioxygen activation via removal of the water ligand as well as 
transition state stabilization of αKG while (2) the interactions involving Gln239 residue 
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help position HIF-1α/CTAD-Asn803 in the proper orientation relative to the generated 
iron oxidant species, which ensure tight coupling.[16] 
Collectively, the previous studies strongly indicate the presence of structural 
elements within the active site of FIH-1, which ensure that the optimal interaction 
between the target HIF-1α/CTAD-Asn803 residue and the iron oxidant species will occur 
for efficient catalysis. To investigate this further, we took a closer inspection of the FIH-1 
structure. Superposition of the crystal structures for the apo (1IZ3, 2.80 Å) and various 
ligand-bound enzyme forms -- αKG-bound (1MZF, 2.40 Å; 1H2N, 2.84 Å) and 
αKG/CTAD-bound (1H2L, 2.25 Å) -- did not reveal significant changes in the protein 
backbone structure of the enzyme as seen before[3,30] but only showed sidechain 
reorientations within the active site. A molecular dynamics study by Park and co-
workers[1] using the apo and αKG-bound structures of FIH-1 suggests that αKG binding 
decreases the flexibility of a certain loop region (we termed the 100s loop) (Figure 4.1A), 
which is in close proximity to the active site. Using the aforementioned FIH-1 structures, 
our initial attempt at online protein dynamics analysis based on the Gaussian network 
model[2], predicted the same loop region to be less flexible in the presence of αKG 
(Figure 4.2). This prediction corroborated with the empirical B-factors, which led us to 
postulate that the 100s loop plays a functional role in the substrate interactions and 
catalysis of FIH-1. As mentioned before, the available crystal structures of FIH-1 
revealed several sidechain reorientations within the active site in the presence of 
substrate[3,30]. The most substantial of these changes is the side chain rotation of Tyr102, 
which incidentally is in the 100s loop  (Figure 4.1B). A movement of roughly 10Å  
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Figure 4.1 (A) Dimer structure of FIH-1 showing the location of the 100s loop. The 
cupin barrel core where the active site is located is shaded in purple. The red sphere is 
Fe(II). (B) Image of the aligned FIH-1/100s loop structures (a: 1MZF, blue, without 
substrate;     b: 1H2L, gray, with substrate) showing the reorientation of Tyr102 in the 
presence of   HIF-1α/CTAD substrate (gray) which stacks the phenol group on top of 





Figure 4.2 Comparison of the experimental and theoretical B-factors of apo (1IZ3) and 
αKG-bound FIH-1 (1H2N) mapped onto the structure. The 100s loop region is encircled. 
The theoretical B-factors were calculated using the Gaussian network model algorithm. 
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repositioned the phenol sidechain of Tyr102 and stacked it right on top of the target     
HIF-1α/CTAD-Asn803 residue as if securing it in place. It also formed H-bond 
interactions with the substrate via the amide nitrogen of Gln807 residue. We predicted then 
that Tyr102 will play a particularly important role in the substrate interactions of FIH-1. 
In this chapter, we report our findings for the role of the 100s loop of FIH-1. 
Using a combination of steady state kinetic analysis of site-directed loop mutants, 
spectroscopy and mass spectrometry, we show the unprecedented involvement of the 
loop, particularly Tyr102, in the efficient turnover of the HIF-1α/CTAD substrate via 
precise substrate positioning of the target HIF-1α/CTAD-Asn803 residue. Based on the 
available data, we propose a modified version of the model for the coupling mechanism 
in FIH-1.  
 
4.2 Experimental Procedure 
4.2.1 Materials 
 The 39-mer peptide corresponding to human HIF-1α 788-826 CTAD 
(DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN) was obtained from 
EZBiolab (Carmel, IN) and was used as the substrate in all activity assays. The synthetic 
peptide contained a Cys à Ala mutation that still preserves the hydrophobic character 
but eliminates any unwanted side-chain interaction with the thiol group. The peptide was 
purified prior to use by RP-HPLC. It was dissolved in 25% acetonitrile/0.2% 
trifluoroacetic acid and purified to at least 95% purity. The concentration of the peptide is 
determined by monitoring the absorbance of Tyr at 293 nm (ε = 2400 M-1cm-1) in 0.1 M 
NaOH[28]. 
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 Iron (II) sulfate (FeSO4), manganese sulfate (MnSO4), and 3,5-dimethoxy-4-
hydroxycinammate were purchased from Acros Organics (Morris Plains, NJ). The rest of 
the chemicals and the snakeskin dialysis membrane were obtained from Fisher Scientific 
(Fair Lawn, NJ). Molecular weight cutoff filters (MWCO) were obtained from Millipore 
(Burlington, MA) and Vivaspin20 ultrafiltration tubes were from Vivascience Sartorius 
(Gottingen, Germany). Primers used for site-directed mutagenesis were designed using 
the Quickchange primer design software of Stratagene (La Jolla, CA) and purchased        
( >90% purity by HPLC) from Integrated DNA Technologies (Coralville, IA). DNA 
sequencing was done by Genewiz, Inc (South Plainfield, NJ). Plasmid purification was 
done using the Qiagen (Hilden, Germany) miniprep kit. 
4.2.2 Site-Directed Mutagenesis 
 The FIH-1 loop mutant plasmids (pET28a) were generated by PCR amplification 
using forward and reverse primers (see Table 4.1) that introduced the site-directed  
 
Table 4.1 Primers used in generating the FIH-1 100s loop mutants 




aThe underlined codon corresponds to the modified amino acid 
` 
mutations. Figure 4.3 shows the location of the mutated residues relative to the metal 
center and the substrate. Removal of the parental plasmid DNA was facilitated by 
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digestion with the restriction enzyme Dpn1. The mutant plasmids were transformed into 
supercompetent XLI-Blue E. coli cells using the heat shock method. The single mutations 
were confirmed by DNA sequencing of the plasmid purified from the transformants. The 
plasmids were then transformed into supercompetent BL21-DE3 E. coli cells. 
 
 
Figure 4.3 Active site of FIH-1 showing the loop residues (blue) targeted for 
mutagenenesis. Lys107 makes indirect contact with the substrate residue Glu801 (not 
shown) via water molecules. Also shown is the substrate target residue HIF-1α/CTAD-
Asn803 (gray). 
 
4.2.3 FIH-1 Expression and Purification 
 BL21-DE3 E. coli cells containing the wild-type FIH-1/ pET28a plasmid were 
grown in Luria-Bertani broth (25 g/L) supplemented with 30 µg/mL kanamycin at 37°C 
with constant shaking. The cells were induced with 0.5 mM IPTG when the OD600 
reached 0.5-0.7 and then further incubated at 37°C for 5 h before harvesting the cells by 
centrifugation. Cell lysis was facilitated by the use of lysozyme (1 mg/mL) and 
sonication on ice for 30 mins with 30 secs break between each burst cycle. Cell debris 
was removed by centrifugation at 15000 rpm (26786g), 4°C for 45 mins. The crude cell 
lysate was dialyzed against 10 mM Tris, pH 8.0 at 4°C and then clarified by 
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centrifugation at 15000 rpm (26786g), 4°C for 10 mins. Purification of the His-tagged 
enzyme was carried out by Ni-affinity chromatography using the BioRad BioLogic LP 
pump system. The enzyme was eluted out using 250 mM imidazole/50 mM 
NaH2PO4/300 mM NaCl, pH 8.04 buffer at a flow rate of 3 mL/min. The enzyme eluate 
was buffer-exchanged against 10 mM Tris, pH 8.0 at 4°C to reduce the imidazole 
concentration. The concentration of the protein was estimated by UV absorbance at 280 
nm using ε280 = 1.22 mL mg-1cm-1 [32].  The His-tag attached to the N-terminus was then 
removed by incubation with thrombin (0.5 U/mg protein) for 24 h at 4°C. The cleaved 
enzyme was obtained by affinity chromatography and was incubated with 50 mM EDTA, 
pH 8.0 at 4°C overnight.  The protein sample was then concentrated at 4°C using the 
Amicon pressure concentrator fitted with 30kDa MWCO filter and finally with the 
Vivaspin20 ultrafiltration tube before it was loaded into the Sephadex G75 resin column 
to obtain the FIH-1 dimer. The purity of the enzyme was checked by SDS-PAGE. 
LC/ESI-MS was also performed to check the molecular masses of the enzyme variants. 
4.2.4 Steady-State Activity Assays 
 FIH-1 activity was assayed by following the formation of the hydroxylated     
HIF-1α/CTAD peptide substrate using the MicroFlex MALDI-TOF MS (Brucker 
Daltonics, Billerica, MA). Unless otherwise specified, steady state assays were done 
under ambient O2 concentrations at 37.0°C in 50 mM HEPES (pH 7.02) maintained at a 
total ionic strength of 100 mM using NaCl. The reaction buffer contained 500 µM αKG, 
2 mM ascorbate, and 50 µM FeSO4. All the buffer constituents were mixed and initially 
incubated at 37.0°C for 3 mins, after which the reaction was initiated by adding enzyme 
to a final concentration of 0.5 µM. The reaction was quenched into 20 µL of 75% 
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CH3CN/0.2% TFA saturated with the MALDI matrix, 3,5- dimethoxy-4-
hydroxycinnamate, at various time points ranging from 20-240 secs. To determine the 
amount of hydroxylated HIF-1α/CTAD, the product of the total CTAD concentration and 
the ratio of the peak intensity for the hydroxylated product relative to the overall peak 
intensities (parent peak and hydroxylated peak intensities) was calculated. The amount of 
hydroxylated HIF-1α/CTAD was plotted versus time and the initial rate was determined 
from the slope of the plot. Steady state kinetics plots were generated by plotting the initial 
rate normalized to enzyme concentration and the substrate concentration. The plots were 
fitted to the Michaelis-Menten equation (equation 4.1): 
                                             𝑣/𝐸 =    !!"#  ×  [!]
!!![!]
                      Equation 4.1 
4.2.5 Circular Dichroism Spectroscopy 
 Protein samples for CD measurements were prepared in 10 mM KH2PO4 (pH 
7.04) with 500 µM αKG and 50 µM MnSO4. Protein concentrations used ranged from 
0.2-0.4 mg mL-1 as measured by UV absorbance at 280 nm (ε280 = 1.22 mL mg-1cm-1). 
The spectra were collected over the wavelength range of 190-250 nm at 37°C using a 
high-transparency quartz cell with pathlength of 0.1 cm on a Jasco J-715 CD 
spectrometer. The instrument was blanked with the buffer solution containing all 
constituents except the protein. All measurements were collected at least three times to 
ensure that the signal is for that of a sample at equilibrium. The average of these 
measurements were taken and used to generate the CD spectra. 
4.2.6 Thermal Shift Experiments 
 Samples for the melt curve run were prepared containing one or two or all of the 
following components: 5 µM FIH-1, 5 µM MnSO4 and 500 µM αKG in 50 mM HEPES 
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pH 7.0. For each sample, 45 µL of the master mix was distributed to each well in the 96-
well qPCR microplate and 5 µL of freshly prepared 5X SYPRO Orange (Sigma-Aldrich, 
5000X stock diluted in dimethylsulfoxide) was thoroughly mixed in. The microplate was 
sealed with a Microseal adhesive film, briefly spun and immediately loaded onto a Bio-
Rad CFX Connect RT-PCR machine and the samples were heated at a rate of 1°C/min 
from 20°C to 90°C. The fluorescence intensity (excitation wavelength: 450-490 nm; 
emission wavelength: 560-580 nm) was monitored as a function of temperature. 
4.2.7 UV/visible Spectroscopy  
 Autohydroxylation monitored by UV/vis spectroscopy was done as previously 
described[5] with minor modifications. Anaerobically prepared protein samples contained 
225 µM FeSO4, 1 mM αKG and 230 µM FIH-1 in 50 mM HEPES pH 7.0. For samples 
with substrate, HIF-1α/CTAD was added to a final concentration of 125 µM. The 
samples were incubated for 30 mins inside the glovebox prior to addition of air- 
equilibrated buffer to initiate autohydroxylation. The reaction was monitored at 583 nm 
for at least 6 hours at room temperature (~23°C). 
4.2.8  Electron Paramagnetic Resonance Spectroscopy  
 Protein samples for X-band EPR measurements were prepared as previously 
described[5] except that the samples were anaerobically reconstituted with FeSO4 instead 
of CuSO4. Stocks of FIH-1, αKG, and HEPES buffer were sealed with rubber septa and 
degassed with argon gas, and brought into a glovebox. FeSO4 and DEANO were brought 
into the glovebox as solids and prepared using degassed H2O and 10 mM NaOH 
respectively. The DEANO concentration was verified by the characteristic UV 
absorbance at 250 nm (ɛ250 = 6500 M-1cm-1)[10,15]. Anaerobic EPR samples containing 
	   101	  
FIH-1/ Tyr102àAla (0.2 mM), FeSO4, (0.18 mM), αKG (1 mM), HIF-1α/CTAD (0.6 
mM), and DEANO (0.50 mM) in 50 mM Hepes pH 7.00 were prepared and aged 
anaerobically at 23°C for 20 minutes to allow NO release from DEANO. The samples 
were capped and flash frozen in liquid nitrogen (LN2) immediately upon removal from 
the glovebox. X-Band EPR data was recorded using a Bruker Elexsys E-500 EPR 
equipped with a DM4116 cavity and a Bruker ER 4118CF-O LHe/LN2 cryostat at 9.624 
GHz frequency, 6.0 mW power, 10 G modulation amplitude, 100 GHz modulation 
frequency, 163 ms time constant at 4K. 
4.2.9 Succinate Coupling Assays 
 Coupling of αKG decarboxylation and HIF-1α/CTAD hydroxylation was 
determined by LC separation and UV detection at room temperature (25°C). Succinate 
produced from quenched-steady state reactions of FIH-1 was detected at 210 nm using a 
Hamilton PRP-X300 anion exclusion column. A linear gradient of 2% acetonitrile and 
0.5 mM H2SO4 was ran through the column at a flow rate of 2 mL/min. Calibration was 
done using serially-diluted fresh succinate stocks in 50 mM Tris with concentrations 
ranging from 65 µM to 520 µM. The steady state assays were done in 50 mM Tris (pH 
7.08 at 37°C) under ambient O2 conditions. HEPES was not used this time because of the 
huge salt peak it produces during LC quantitation, which complicates subsequent 
succinate peak analysis. Ascorbate was also left out of the reaction mix for the same 
reason. Wild type enzyme was used as the control to ensure that the conditions used still 
support coupled enzymatic activity. The reaction components included 1 µM for all 
enzyme concentrations except for Tyr102àAla mutant (25 µM), 50 µM FeSO4, 500 µM 
αKG and 200 µM HIF-1α/ CTAD. The hydroxylated HIF-1α/CTAD (CTAD-OH) was 
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monitored using MALDI-MS as described above. The coupling ratio (C) is defined as the 
ratio of the rate of succinate production (as given by the slope of the line) over the rate of 
CTAD-OH production. 
 
4.3 Results and Discussion 
4.3.1 The 100s Loop Mutations Affected Substrate Binding and Catalysis of FIH-1 
The molecular masses of the generated FIH-1 loop variants were determined by 
LC/ESI-TOF mass spectrometry (supplemental Figure 4.11). The observed masses 
correspond well with the expected masses for each enzyme species: wild type FIH-1 
(observed mass 40567.3 Da; expected mass 40566.7 Da), Tyr102àPhe/FIH-1 or Y102F 
(observed mass, 40551.4 Da; expected mass, 40550.7 Da), Tyr102àAla/FIH-1 or Y102A 
(observed mass, 40474.5 Da; expected mass, 40474.6 Da) and Lys107àAla/FIH-1 or 
K107A (observed mass, 40510.5 Da; expected mass, 40509.6 Da).   Steady state kinetic 
assays of the variants were conducted to test the role of the 100s loop in substrate binding 
and catalysis of FIH-1 (Figure 4.4). The kinetic parameters were measured at pH 7.02, 
37.0°C in 50 mM HEPES, with the total ionic strength fixed at 100 mM using NaCl. 
Fixed concentrations of FeSO4, αKG, and O2 were used while the HIF-1α/CTAD 
substrate concentration was varied.  As the Fe2+ and αKG concentrations were saturating, 
but the O2 concentration was fixed at the ambient level (ca. 217 µM), the reported rate 
constants summarized in Table 4.2 are apparent. 
The data shown in Figure 4.4 clearly indicate that the Ala mutations of the loop 
residues affected FIH-1 activity to different extents whereas the variant with the 
conservative Phe mutation at position 102 exhibited wild type-like activity. Wild type 
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FIH-1 exhibited steady-state rate constants that were in good agreement with those 
previously reported, with kcat = 39 ± 1 min-1 and kcat/KM = 0.49 ± 0.03 min-1 µM-1. The 
conservative Tyr102àPhe mutant exhibited modest effects on enzyme activity, as kcat                  
(42 ± 2 min-1) was indistinguishable from that of WT-FIH-1 while kcat/KM (0.15 ± 0.01 
min-1 µM-1) was decreased by a factor of 3. This may be due to some minor changes in 
electrostatics upon loss of the hydroxyl group, which is shown in crystal structures to 
form an H-bond with the substrate via the amide group of Gln807 residue.  In contrast, the 
Tyr102àAla mutant drastically affected steps throughout the catalytic cycle, as it 
exhibited greatly reduced kinetic constants relative to wild type FIH-1, with more than 
150-fold reduction in kcat  (< 0.2 min-1) and a 3000-fold reduction in kcat/KM (1.3 × 10-4 
min-1 µM-1).  Because both kinetic parameters were significantly reduced, the apparent  
 
Figure 4.4 Steady state kinetics plots for wild type FIH-1 and the loop variants. The data 
were fitted using the Michaelis-Menten equation. The reaction was done at 37°C in       
50 mM HEPES pH 7.02 containing 50 µM FeSO4, 500 µM αKG, 2 mM ascorbate,       
0.5 µM enzyme for WT and Y102F, 1 µM enzyme for K107A, 20 µM enzyme for 
Y102A, and 0-450 µM HIF-1α/CTAD. The assay experiments were at least done in 
triplicate. 
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Table 4.2 Summary of the parameters generated from the fit of the Michaelis-Menten 
plots for wild type FIH-1 and the loop variants. KD for HIF-1α/CTAD was also included 
for comparison to the KM for HIF-1α/CTAD. 
 




kcat/KM ( min-1  µM-1) 
HIF-1α/CTAD 
KD (µM)b 
2-O       HIF-1α/CTAD 
WT FIH-1   39 ± 1 79 ± 6 17 ± 2 0.49 ± 0.03 91 ± 5 
Tyr102àPhe   42 ± 2 288 ± 30 10 ± 3 0.15 ± 0.01 204 ± 8 
Tyr102àAla   < 0.2 > 500 9 ± 1a 0.00013 ± 0.00001 > 500 
Lys107àAla   27 ± 2 > 500 8 ± 3 0.06 ± 0.002 > 500 
a Value determined by fitting the the uninhibited part of the steady-state kinetics plot 
using the Michelis-Menten equation (equation 4.1). 
bValues determined by monitoring intrinsic fluorescence quenching (or Trp quenching) 
assays (supplemental Figure 4.13). 
 
implication is that the Ala mutation at residue 102 affected a common kinetic step, which 
according to the proposed mechanism for FIH-1 (Scheme 1.1), corresponds to the oxygen 
activation step. Overall, the kinetics data strongly suggest a very important role for the 
bulk of Tyr102 residue on FIH-1 activity. The Lys107àAla mutant principally affected 
steps involved in substrate binding, as there was only a slight decrease in kcat                 
(27 ± 2 min-1) and an 8-fold decrease in kcat/KM (0.06 ± 0.002 min-1 µM-1) relative to wild 
type FIH-1. The substrate binding affinity of the mutant was apparently reduced at least 
5-fold. This might be due to some minor substrate contact alterations. In the crystal 
structures, Lys107 residue is shown to form indirect interactions with Glu801 of HIF-1α/ 
CTAD via water molecules.  
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The KM values for αKG (see supplemental Figure 4.12 for the steady state assay 
plots) were essentially unchanged or at the most, only slightly slower relative to wild-
type FIH-1 except for the slow Tyr102àAla variant, which apparently exhibited strong 
partial substrate inhibition at concentrations above 50 µM αKG. Lys107àAla mutant 
seemed to exhibit some inhibition at really high αKG concentrations (> 500 µM) but not 
as dramatic as the slow variant. The steady state kinetics data for Tyr102àAla variant  
(supplemental Figure 4.12) fitted well to a partial uncompetitive inhibition model[41,43] 
(supplemetal Equation 4.3) wherein excess αKG binds like an inhibitor to an already 
αKG-bound enzyme form. The model may or may not describe what is actually 
happening at high αKG levels but it can be a good start to account for the observation.  
The apparent KM for αKG upon curve-fitting to equation 4.3 is greater (52 ± 39 µM) than 
wild type. On the other hand, fitting of the non-inhibited data points using the Michaelis-
Menten equation gave a KM value (9 ± 1 µM) that is reasonably close to that of wild type 
enzyme. This apparent partial substrate inhibition is bewildering and interesting at the 
same time as Tyr102 residue is quite far from the metal center (at least 9 Å away) and 
thus, is not expected to be directly involved in αKG binding. Indeed, this notion is 
supported by two independent binding assays based on intrinsic fluorescence quenching 
(or Trp quenching) assay as well as absorbance change at 490-500 nm monitored by UV-
vis spectroscopy (supplemental Figures 4.14 and 4.15). The KD values obtained were 
essentially similar for both wild type (35 ± 2 µM; 32 ± 9 µM) and mutant enzyme   
(22 ± 2 µM; 25 ± 10 µM). Cu-EPR spectroscopy data (supplemental Figure 4.16) also 
provided support, as the spectral lineshapes were very similar relative to wild type under 
conditions of low and high αKG concentrations, indicating that the metal coordination 
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geometry was not altered by the mutation. Loss of the bulk at position 102 could have 
resulted in a more open and thus more solvent accessible active site. This raises the 
possibility of two αKG molecules binding to the active site metal, which results to 
inhibition. However, the initial Cu-EPR data did not support this hypothesis. Global 
HDX data (supplemental Figure 4.17; Tables 4.10A and B) did not reveal any large-scale 
structural changes at high αKG concentrations that could have affected activity. The slow 
variant appears to be slightly more solvent accessible than wild type which is expected 
given the removal of the bulk at position 102. Both wild type and the slow variant 
showed a slightly higher number of exchangeable protons at low αKG concentrations 
suggesting a few small-scale changes. So far, the only plausible explanation we can 
arrive at is that removal of the bulk of Tyr102 induced some αKG-dependent, localized 
structural rearrangements that negatively affected the activity possibly via disruption of 
substrate binding but not to such an extent as to completely abolish enzyme activity.  This 
is reminiscent of homotropic allostery to some extent[42]. The proposed αKG-dependent, 
localized structural rearrangements likely contribute to the observed slight reduction in 
the thermal stability of this slow variant relative to wild type upon αKG binding as noted 
from thermal shift data (Figure 4.6; Table 4.3). Initial binding experiments seem to 
support this hypothesis of an αKG-dependent disruption of substrate binding 
(supplemental Figure 4.18) though much still needs to be done to wrap up this part of the 
study. Nevertheless, it is quite clear at this point that the residue at position 102 has a 
critical role on FIH-1 activity.  
Because of the drastic effect of a single residue mutation on enzyme activity as 
observed for the Tyr102àAla mutant, we wanted to know if the effect was due to some 
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widespread perturbations in the enzyme structure. To test for these, the CD spectra for 
wild type FIH-1 and the loop mutants were measured at pH 7.04 in 10 mM KH2PO4 
buffer. To prevent untoward oxidation reactions, Mn2+ was used in place of Fe2+ for all 
samples. Wild type FIH-1 exhibited two negative CD features (Figure 4.5) near 208 nm 
and 222 nm, with a tailing positive feature below 200 nm, as expected for the mixed α/β 
secondary structure observed crystallographically[3,30]. Each of the loop mutants exhibited  
a CD spectrum that was similar to that of wild type FIH-1, indicating that the overall 
protein structure was unaffected by point mutations.  This was further supported by 
thermal stability data obtained through monitoring of protein unfolding using a  
 
Figure 4.5 Far-UV CD spectra of wild type FIH-1 and the loop variants. Samples 
contained 50 µM MnSO4, 500 µM αKG and 0.2-0.4 mg/mL enzyme in 10 mM KH2PO4 
pH 7.04 and were analyzed at 37°C.  
  
hydrophobic fluorescent dye and RT-PCR. Similar to wild type, the apparent melting 
temperatures for all the variants were elevated by at least 3°C in the presence of αKG 
(Figure 4.6; apparent melting temperatures summarized in Table 4.3). Both Tyr102àAla 
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Figure 4.6 Comparison of the apparent melting temperatures determined from thermal 
shift assays for wild type FIH-1 and the loop variants in the presence of αKG. The 
thermal stability of the assay mix containing one or all of the components: 5 µM FIH-1, 
50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0, was monitored using SYPRO 
Orange dye with an RT-PCR machine.  
 
Table 4.3 Apparent melting points of FIH-1 loop variants determined from thermal shift 
assays.  
 
 Tm, app (°C)a  
Apo FIH-1 
Tm, app (°C)a  
(Mn+αKG)FIH-1 
WT FIH-1 47 ± 0.3 52.5 ± 0.5 
Tyr102àPhe 48 ± 0.5 52 ± 0.1 
Tyr102àAla 46 ± 0.6 49.5 ± 0.5 
Lys107àAla 45 ± 0.3 49 ± 0.5 
aThe reported values are the average of three replicate samples. 
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and Lys107àAla mutants exhibited a slight reduction (about 3°C difference) in thermal 
stability compared to wild type upon αKG binding, which might mean that the flexibility 
associated with these residues have some role in enzyme function, most likely on 
substrate binding. The decrease might be due to some small-scale structural 
rearrangements upon mutation. Nevertheless, the general trend of increasing thermal 
stability in the presence of αKG for all the loop variants tested points to an essentially 
similar folded structure that is still capable of binding αKG. Collectively, these data 
supported the notion that for the loop mutants, any drastic effect on enzyme activity is 
likely not due to large-scale changes in the protein structure. 
4.3.2 Loss of Bulk in the Loop Residue, Tyr102, Did Not Affect Oxygen Activation  
The very low enzyme activity exhibited by Tyr102àAla mutant prompted the 
question of whether dioxygen activation was compromised in this variant. An indirect 
measurable indication of dioxygen activation is the amount of succinate produced as a 
result of αKG oxidation.  During uncoupling events, O2 activation proceeds to produce 
succinate but does not proceed further to produce an equimolar amount of hydroxylated 
substrate.  Consequently, less hydroxylated product does not automatically indicate less 
succinate, or reduced ability to activate O2. 
To indirectly monitor O2 activation, succinate quantitation assays combined with 
UV-vis and {FeNO}7 EPR spectroscopy were conducted. UV-vis spectroscopy was used 
to monitor the autohydroxylation of FIH-1, which is dependent on the presence of iron, 
αKG, and O2[4,32] and which is also indicative of oxygen activation albeit at a 
significantly reduced rate. Anaerobic preparation of the (Fe+αKG)FIH-1 complex 
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initially resulted in a light violet-colored solution with an absorption peak centered at 500 
nm (supplemental Figure 4.19) similar to that observed for the related enzyme TauD[6]. 
This absorption arises from the metal to ligand charge transfer between the T2g(π) orbitals 
of Fe(II) and the empty low-lying π* orbitals of αKG[13]. Wild-type and the conservative 
mutant Tyr102àPhe formed the purple autohydroxylated species at comparable rates 
(Figure 4.7A; Table 4.4) while Tyr102àAla mutant formed the chromophore species at a 
slightly reduced rate, which indicates that this slow enzyme variant is still capable of O2 
activation. The purple chromophore species was previously identified to be the Fe(III)-O-
Trp296 protein species in wild type FIH-1[32] and is assumed to be the same chromophore 
species for the loop variants given that the λmax values are reasonably similar. The 
corresponding broad absorption peak for the generated autohydroxylation species of the 
slow mutant was centered at around 570 nm (Figure 4.7B), which is slightly blue-shifted 
compared to wild type (583 nm) and Tyr102àPhe (580 nm) (supplemental Figure 4.20). 
This may be due to perturbations in the steric crowding within the active site upon loss of 
the bulk of Tyr102 residue. 
Results from end point succinate assays further supported the observation that 
Tyr102àAla mutant can still activate oxygen as it was observed to produce succinate 
although at an apparently slower rate than wild type and the other two loop mutants 
(Table 4.5). Together with the previous kinetic and autohydroxylation data, this 
observation of reduced succinate production hinted at a slower rate of O2 activation, 
which points to a possible indirect role of Tyr102 residue on oxygen activation. Its role is 
likely structural in nature. Close inspection of the FIH-1 structure revealed Tyr102 as one 
of the residues lining the enzyme’s proposed solvent channel (supplemental Figure 4.21), 
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Figure 4.7 FIH-1 autohydroxylation monitored by UV-vis spectroscopy. (A) Auto-
hydroxylation timecourse plots for wild-type FIH-1 and the Tyr102 variants monitored at 
583 nm. (B) Autohydroxylation spectra for the loop variant Tyr102àAla. The arrow 
indicates the increase in the absorption signal of the chromophore with a λmax at 570 nm. 
The spectra was obtained over a period of several hours after air exposure at RT (~23°C)  
of the anaerobically prepared samples (230 µM enzyme, 225 µM FeSO4, 1 mM αKG) in 
50 mM HEPES pH 7.0.  
 
 
Table 4.4 Summary of the autohydroxylation rates for wild-type and the Tyr102 variants.  
 
 Autohydroxylation Ratea 
(µM min-1) 
WT FIH-1 1.51 ± 0.35 
Tyr102àPhe 0.91 ± 0.13 
Tyr102àAla 0.66 ± 0.10 
Lys107àAla N.D. 
aThe reported values were determined from the slope of the line generated using the early 
time points up to 15 mins. 
N.D., not determined. 
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Table 4.5 Comparison of the amounts of succinate and hydroxylated HIF-1α/CTAD 
produced after 15 mins using 1 µM enzyme for all enzymes except Y102A (25 µM) with 
50 µM FeSO4, 500 µM αKG,	  and	  200 µM HIF-1α/CTAD in 50 mM Tris pH 7.08 at 
37°C. Negative controls contained all components except αKG,	  which	  was	  replaced	  by	  






WT FIH-1 59.4 ± 0.5 46.5 ± 0.05 
Tyr102àPhe 52.2 ± 0.1 46.3 ± 0.03 
Tyr102àAla 18.4 ± 0.3c 4.8 ± 0.08c 
Lys107àAla 51.8 ± 0.3 46.4 ± 0.06 
 
a[Succinate] was determined by HPLC quantitation. 
b[CTAD-OH] was obtained using MALDI/TOF-MS as described in the experimental 
procedure. 
cReaction mix was further incubated for 3 hours at 37°C. The following are the results 
obtained after 3 hours incubation: [succinate] = 50.4 ± 0.09 µM; [CTAD-OH] = 11.5 ± 
0.07 µM.  
  
which overlaps with site 1 of the substrate binding groove[3]. The said channel, which has 
never been formally identified in FIH-1, is most likely a transient one that really only 
comes into shape upon substrate binding.  The substrate-induced structural changes 
possibly impose active site accessibility of O2, limiting the binding configurations it can 
assume. A more open channel, as when the bulk at position 102 is removed, will 
conceivably result to O2 having more freedom to sample different non-productive binding 
configurations, which can in turn slow down O2 activation. 
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To demonstrate the intact ability of Tyr102àAla mutant to productively bind 
oxygen, {FeNO}7 EPR spectroscopy analysis was performed. Nitric oxide (NO) was used 
as the O2 mimic. NO binds to Fe2+ in non-heme O2 activating enzymes with similar 
geometry to that of bound O2 to form a spectroscopically accessible S = 3/2 metal 
center[7-9]. The EPR lineshape and the rhombic zero-field splitting parameter (E/D) of 
{FeNO}7 centers in Fe2+ enzymes are sensitive reports on the geometry of the {FeNO)7 
center.[7,8,11] As the EPR line shape and E/D ratio are dominated by large zero field 
splitting, the effective g-values (geff) are centered near g = 4. As the S = 3/2 electronic 
structures were axial (E/D < 0.1), the observed geff values (gx, gy,) were related to zero-
field splitting (E/D) using the relationship in equation 4.2[12].  






]         Equation 4.2 
Anaerobic addition of NO to (Fe+αKG) Tyr102àAla and (Fe+αKG+CTAD) Tyr102àAla 
complexes resulted to a yellow colored-solution and complex EPR line-shape near g = 4 
(Figure 4.8; parameters summarized in Table 4.6). The EPR spectrum of (Fe+αKG+NO) 
Tyr102àAla sample was highly heterogeneous and exhibited several S = 3/2 species at 
geff = 4.29, 3.75 (E/D = 0.047), 4.11, 3.93 (E/D = 0.015), and 4.06, 4.00 (E/D = 0.005). In 
comparison, the spectrum for wild type (Fe+αKG+NO)FIH-1] sample displayed a line-
shape arising from a single S = 3/2 species with geff = 4.11, 3.92 (E/D = 0.016). In the 
presence of substrate, the spectrum of (Fe+αKG+NO+CTAD) Tyr102àAla complex 
displayed only one S = 3/2 species with geff = 4.06 and 3.99 (E/D = 0.005), suggesting 
that there was one dominant geometry for bound gas, likely arising from steric constraints 
provided by the target asparagine residue. Because the spectra of Tyr102àAla mutant and 
wild type FIH-1 upon HIF-1α/ CTAD binding are similar, it suggests that the slow  
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Figure 4.8 X-band EPR spectra for Tyr102àAla mutant (Y102A). The sample contained 
200 µM enzyme, 180 µM FeSO4, 1 mM αKG, and 500 µM DEANO in 50 mM HEPES 
pH 7.00 and aged anaerobically at 23°C for 20 minutes to allow NO release from 
DEANO in the presence or absence of 600 µM HIF-1α/CTAD. 
 
Table 4.6 Comparison of the X-band EPR parameters for NO complexes of wild type 
FIH-1 versus Tyr102àAla mutant (Y102A).  
 




(Fe+αKG+NO)WT 4.11, 3.92 0.016 










(Fe+αKG+NO+CTAD)Y102A 4.06, 3.99 0.005 
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mutant is still able to form the proper gas binding environment which leads to turnover. 
Together with the results from the auto-hydroxylation experiment, the data indicates that 
the Tyr102àAla mutation did not significantly impair the first part of the catalytic cycle 
in the proposed mechanism, which involves oxygen activation and the subsequent 
succinate production. 
4.3.3 Loss of Bulk in the Loop Residue, Tyr102, Affected Coupling  
To account for the drastically reduced activity of the Tyr102àAla variant despite 
retaining the ability to activate oxygen, we turned to steady state assays to check for 
coupling by comparing the amount of succinate produced to the amount of hydroxylated 
substrate. Under tight coupling conditions, equimolar amounts of succinate and 
hydroxylated HIF-1α/CTAD will be observed to give a coupling ratio (C) close to unity. 
Uncoupling will result to higher C values. Succinate quantitation experiments revealed 
that Tyr102àAla mutant could still produce succinate albeit at a slower rate (Table 4.5; 
coupling ratios summarized in Table 4.7). Nevertheless, it was able to produce as much 
succinate as wild type and the other two mutants upon longer incubation (~3 hours) in 
agreement with the previous autohydroxylation data, which indicates that oxygen 
activation still occurs for this slow variant. The C value was significantly elevated (C = 
4.1 ± 0.35) for Tyr102àAla mutant whereas wild type was tightly coupled (C = 0.97 ± 
0.05) as previously observed[5]. The other two loop variants, Tyr102àPhe  (C = 0.93 ± 
0.08) and Lys107àAla (C = 1.17 ± 0.2) were also similarly coupled. This data indicates 
that Tyr102àAla mutant uncouples appreciably which would explain the observed 
reduced hydroxylated product yield. In fact, endpoint assay results (Table 4.7) show that 
even with 50 µM enzyme, this variant only produced less than 25% of hydroyxlated   
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Table 4.7 Summary of the coupling ratios and yield of hydroxylated CTAD for FIH-1 
loop variants. 
 
 Ca % yieldb 
WT FIH-1 0.97 ± 0.05 99 
Tyr102àPhe 0.93 ± 0.08 94 
Tyr102àAla 4.1 ± 0.35 21 
Lys107àAla 1.17 ± 0.2 96 
 
a C = [succinate]/[CTAD-OH]; determined under steady state conditions 
b end-point assay conditions: 50 µM enzyme, 100 µM FeSO4, 2 mM ascorbate, 500 µM 
αKG,  99 µM HIF-1α/CTAD, 50 mM HEPES pH 7.0 (total ionic strength maintained at 
100 mM with NaCl); incubated for 3 hours at 37°C; samples were taken and quenched at 
the following time points: 2, 5, 10, 30, 60, 180 mins; values reported were based on 
samples quenched after 3 hours;  % yield is calculated based on the fraction of 
conversion to CTAD-OH, i.e. 99% yield means [CTAD-OH] = 98 µM.  
 
HIF-1α/CTAD after 3 hours of incubation whereas wild type and the other two loop 
variants achieved almost complete conversion of the substrate in less than 10 mins. 
The elevated coupling ratio observed for the Tyr102àAla mutant points to an 
unprecedented role of this residue on enzyme turnover via substrate positioning. A 
similar observation in our lab was previously seen for the slow Asn variant of Gln239 
residue[16,31], which like Tyr102àAla mutant also uncoupled considerably. Based on the 
crystal structures, the sidechain of Gln239 gets reoriented upon substrate binding to form 
two H-bond interactions with the amide group of HIF-1α/CTAD-Asn803, which ensures 
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that the target residue is properly positioned for efficient iron oxidant attack. In a similar 
manner, the significant sidechain displacement of Tyr102, which stacks it right on top of 
HIF-1α/CTAD-Asn803 (Figure 4.1B), is also crucial in positioning the target residue as 
strongly implied by the coupling data. The steric stacking interaction appears to be CH/π 
in nature as the aromatic plane of the phenol side chain is stacked close (~4Å) (Figure 
4.9A) to the β-carbon of Asn803 residue[19,20]. Based on the crystal structures, the target 
Asn residue is positioned such that the pro-R hydrogen atom is ideally pointed towards 
the aromatic ring of Tyr102 residue. The use of steric interactions by FIH-1 to position the 
substrate is reminiscent of the observation previously made on the related enzyme TauD 
regarding a Phe residue, which like Tyr102, also lies on the other side of the substrate 
directly opposite the iron metal[40]. Comparison of the placement of both residues in each 
case relative to the substrate and the iron metal show striking similarities (Figure 4.9). 
The Ala mutation in both cases resulted in enhanced uncoupling.  
 
Figure 4.9 Comparison of the steric placement relative to the substrate in (A) FIH-1 
versus (B) TauD.  
 
The significant effect of the Tyr102àAla mutation on FIH-1 activity, prompted us 
to search the literature to determine whether Tyr102 residue is conserved across species. 
Indeed, after BLAST alignment of FIH-1 sequences from representative samples  
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Table 4.8 BLAST protein sequence alignment of the 100s loop segment of FIH-1 from 
five representative species. The Tyr102 residue is in bold and underlined. 
 
Species FIH-1 100s loop sequence 
H. sapiens KFLYYDEKKMGN 
M. muculus KFLYYDEKKMGN 
C. crassius KFLYYDEKKMAN 
H. occelatum KFLYYDEKKMVN 




obtained from UniProt, we found Tyr102 to be conserved across species from fish to 
mammals and even insects (Table 4.8) although the sequence of the latter must be 
regarded with caution as it is evidently divergent. Nonetheless, this finding supported a 
critical role for Tyr102 residue in FIH-1 activity. 
4.3.4 Precise Substrate Positioning is Key to Tight Coupling of αKG Oxidation and 
Substrate Hydroxylation in FIH-1 
It appears that efficient catalysis in the form of hydoxylated HIF-1α/CTAD relies 
heavily on the precise positioning of the target residue as the reactive iron oxidant species 
must be sufficiently juxtaposed to effectively promote hydrogen atom abstraction from an 
unactivated carbon and the subsequent hydroxyl radical rebound. Single mutations of 
Tyr102 and Gln239 residues independently resulted to a significantly reduced enzyme 
activity, which in both cases were attributed to impaired substrate positioning. Thus, it 
becomes apparent that the enzyme utilizes a combination of electrostatic and steric  
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Figure 4.10 Image of aligned FIH-1 structures (1MZF, blue (without substrate); 1H2L, 
light grey (with substrate)) showing the rotation of Tyr102 and the downward movement 
of the amide sidechain of Gln239 in the presence of HIF-1α/CTAD (in dark grey) to 
properly position the target residue Asn803 via steric and H-bond interactions respectively.  
The iron is shown as a red sphere coordinated to the facial triad motif and αKG (green). 
Also shown is Asp201 forming an H-bond interaction with the backbone amide of Asn803 
residue. 
 
interactions just to position the target Asn803 residue correctly (Figure 4.10). Our group 
previously alluded[16] that the interaction between substrate and enzyme residues within 
the active site of FIH-1 might be the link between αKG oxidation and substrate 
hydroxylation. Combining the previous published data from the lab with observations 
made in this study enables us to be more specific about that important link in FIH-1. The 
precise substrate positioning afforded by both Tyr102 and Gln239 is the key link to ensure 
that αKG oxidation subsequent to substrate binding is efficiently coupled to HIF-1α/ 
CTAD hydroxylation.  Apparently, neither one of these residues can independently 
secure the target Asn803 residue in a productive orientation as mutation of one is enough 
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to cause uncoupling. It might well be that these residues comprise a structural element of 
the enzyme, the sole purpose of which is to precisely position the substrate for efficient 
hydrogen abstraction by the iron oxidant species. Inspection of the crystal structures 
would seem to include the primary sphere residue Asp201 in this group as it forms a 
hydrogen bond with the amide backbone of HIF-1α/CTAD-Asn803 (Figure 4.10). The 
need to precisely position the substrate points to a distance-dependent orientation 
requirement of the hydrogen abstraction event, which is likely critical to the ability of the 
putative ferryl species to form the O-H bond[39,40].  
To lend structural support to the proposed substrate positioning model, we 
attempted to obtain the crystal structures of the Tyr102àAla mutant with and without 
substrate. Unfortunately, the supposedly substrate-bound structure (2.7Å; already 
submitted to the PDB bank by Cornelius Taabazuing) showed no density where the 
substrate is expected to be located, meaning it had no substrate occupancy. This is 
probably because of the very low substrate affinity of this mutant. Nonetheless, the 
protein backbones (wild type vs Tyr102àAla mutant) were found to be superimposable 
and so just based on this information, the best conclusion we can arrive at is that the 
observed drastic effect on enzyme activity can be ascribed to the loss of the phenol side 
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4.4 Conclusions and Future Directions 
 The loop region in FIH-1 termed the 100s loop was investigated in relation to its 
role in substrate interactions and catalysis. Precedent for the study came from a previous 
computational work demonstrating reduced loop flexibility upon αKG binding[1].  Steady 
state kinetic data strongly indicate that the 100s loop is important for substrate binding 
and catalysis. The results particularly revealed a critical role for the bulk at position 102 
as the Tyr102àAla mutation drastically reduced enzyme activity whereas the conservative 
Tyr102àPhe exhibited wild type-like behavior. The slow variant exhibited reduced 
thermal stability relative to wild type in the presence of αKG as shown by thermal shift 
data, which suggests that the flexibility associated with this residue or loop region is 
important for enzyme activity. Other experiments can be done such as thermal unfolding 
by CD spectroscopy or differential scanning calorimetry to provide further data on the 
effect of Tyr102àAla mutation on conformational stability. The slow variant also 
apparently exhibited an unexpected partial substrate inhibition with αKG, which might 
have something to do with its observed reduced thermal stability. At least two hypotheses 
have been proposed for the mechanism of partial inhibition: (1) inhibition is due to two 
αKG molecules bound to the active site or (2) inhibition is due to αKG-dependent local 
conformational effects, with the latter hypothesis being considered the most plausible in 
the current study.  The mutation induced negligible effects on global structure relative to 
wild type as noted from CD spectroscopy and global HDX-MS data. However, the 
possibility still remains that the mutation somehow altered loop dynamics; removal of the 
bulk of Tyr102 likely induced some αKG-dependent, localized structural rearrangements 
that negatively impacted the already reduced activity via disruption of substrate binding 
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at high αKG levels. The disruption being referred to here is probably in addition to the 
substrate positioning effect of Tyr102 residue. Initial substrate binding experiments at low 
and high αKG seem to support this hypothesis but much work still needs to be done to 
prove or disprove it. For one, additional binding experiments have to be done to ensure 
robustness of the initial data. The proposed αKG-dependent, small-scale rearrangements 
in the slow variant might be uncovered by low-resolution tools like limited proteolysis, 
which can then be compared and contrasted to that of wild type enzyme. On a much 
grander scale, the rate of conformational exchange for the loop residues of wild type 
versus Tyr102àAla mutant can be measured either by NMR or local HDX-MS to probe 
any alterations in the loop dynamics that somehow affected αKG interactions and 
ultimately substrate binding. Additionally, the αKG ligand stoichiometry of wild type 
and Tyr102àAla mutant can be measured by UV-vis spectroscopy using the method of 
continuous variations to prove or disprove the first hypothesis that the inhibition is due to 
two αKG molecules bound to the active site. So far, initial Cu-EPR data did not support 
this hypothesis but was not completely ruled out. 
Further kinetic and biophysical characterization of the slow loop variant revealed 
an unprecedented role for Tyr102 in enzyme activity via substrate positioning. The 
Tyr102àAla mutation did not significantly impair the first part of the catalytic cycle 
which leads to αKG oxidation but drastically affected and thus uncoupled the second part 
which leads to HIF-1α/CTAD hydroxylation. Although the mutant did not lose its ability 
to activate dioxygen, it did so at an apparently slower rate as suggested by kinetic, 
spectroscopic and coupling data so one cannot entirely rule out the possible involvement 
of Tyr102 residue in oxygen activation. Its involvement is probably linked to its structural 
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placement within the proposed solvent channel of FIH-1, which is being speculated in 
this study as the enzyme’s O2 gate that limits the gas to bind predominantly in a 
productive orientation upon substrate-induced rearrangements. Molecular dynamics 
simulations might be able to formally identify this proposed O2 pathway in FIH-1. As no 
single residue in the proposed channel seems to act like the lone guard of the “gate” 
based on the structures, use of double (i.e. Tyr103àTrp/Glu105àGln) or triple residue 
mutations that will limit accessibility is probably the way to test this for O2 kinetics 
should the computational studies give favorable results. Currently, there are only indirect 
evidences but no direct ones to demonstrate that substrate binding in FIH-1 causes O2 
activation to happen at an appreciable rate as observed for the other dioxygenases. This is 
another area of FIH-1 research that can be done for future studies to provide unequivocal 
support of the enzyme’s substrate triggering phenomenon. It would also pave the way to 
tackle the question of whether the substrate triggering mechanism in FIH-1 is dependent 
on substrate positioning. 
That Tyr102 residue is found to be sterically involved in substrate positioning is 
consistent with the initial observation from crystal structures, which showed significant 
rearrangement for this residue upon substrate binding. In the presence of HIF-1α/CTAD, 
the phenol side chain of Tyr102 is shown to be stacked against HIF-1α/CTAD-Asn803 as if 
securing the target residue in the proper orientation for efficient oxidation by the iron 
oxidant species. This steric stacking interaction is most likely CH/π in character. It might 
be possible to characterize this interaction in FIH-1 using a combination of quantum 
chemical calculations and molecular dynamics simulations if only crystal structures of 
the Tyr102àPhe and Tyr102àAla variants bound to substrate are available. Based on the 
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available data, we postulated that proper substrate positioning afforded by FIH-1 residues 
within the active site including Tyr102 ensures tight coupling between αKG oxidation and 
HIF-1α/CTAD hydroxylation. This corroborates as well as extends the substrate 
positioning model previously implied in our lab, which identified Gln239 residue to 
contribute via H-bond interactions[16]. The original premise of the model is that tight 
coupling of αKG oxidation to substrate hydroxylation is ensured via proper substrate 
positioning of HIF-1α/CTAD-Asn803 by Gln239 residue relative to the iron oxidant 
species.  The data obtained in this study allowed for a slight modification in the proposed 
model; that FIH-1 maintains tight coupling by employing structural elements within the 
active site, which not only provide electrostatic (Gln239 and possibly Asp201) but steric 
(Tyr102) interactions as well, to precisely position the substrate relative to the iron oxidant 
species. One way to further test the steric role of Tyr102 in substrate positioning is to 
generate variants at this position that will replace Tyr with hydrophobic residues 
intermediate in size between Ala and Phe residues as was done in an earlier work on 
TauD[40]. A strikingly similar observation as that for Tyr102 was noted for Phe159 residue 
of TauD, which showed increasing trend of uncoupling with decreasing bulk at this 
position[40]. Use of a substrate specifically deuterated at the target Asn residue position 
would give very informative kinetic isotope results but generation of such a peptide 
substrate is extremely difficult though not impossible. 
The requirement of the enzyme for both electrostatic and steric interactions to 
secure HIF-1α/CTAD-Asn803 residue in place makes sense given the relative flexibility 
of the extended conformation assumed by this region (site 1) of the substrate as discussed 
in the previous chapter. Enzyme uncoupling due to impairment of the productive binding 
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orientation of the target residue might conceivably result in the increased residence time 
of the generated iron oxidant species although for Tyr102àAla variant, loss of the bulk 
probably enhanced solvent accessibility of the active site and so the reactive species 
could just as easily get hydrolyzed by solvent molecules. However, using deuterated 
solvent might slow the rate of hydrolysis and possibly enable the detection of the elusive 
iron oxidant species in FIH-1 by stopped flow UV-vis spectroscopy. Fortunately, the 
slow variant did not lose its ability to activate dioxygen and thus can still generate the 
reactive iron species. It might even prove advantageous that the mutant can do so at an 
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4.5 Appendix 
4.5.1 Abbreviations 
BLAST, basic local alignment search tool; 
EPR, electron paramagnetic resonance; 
DEANO, diethylamine nitric oxide; 
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4.5.2 Supplemental 
4.5.2.1 LC/ESI-TOF mass spectrometry to determine molecular mass of FIH-1 
 
  
Figure 4.11 ESI/TOF mass spectra of wild type FIH-1 and loop mutants. LC-MS 
samples were prepared by dilution in 10 mM ammonium acetate buffer pH 7.4 to give a 
final concentration of 20 µM FIH-1 and then injected into the RP-C4 column equilibrated 
with 0.1% formic acid at RT (~23°C). Quick gradient elution was performed with 
acetonitrile/0.1% formic acid solvent for 10 mins. The masses were analyzed using the 
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4.5.2.2 Steady-state kinetic assays of FIH-1 to determine the KM for αKG 
  
 
Figure 4.12 Steady state kinetics plots for wild type FIH-1 and the loop variants. The 
data were fitted using the Michaelis-Menten equation giving apparent KM values of  
17 ± 2 µM for wild type, 10 ± 3 µM for Y102F, and 8 ± 3 µM for K107A. For Y102A, 
the plot was fitted to a partial uncompetitive inhibition equation[41,43] where kcat and ki 
correspond to the catalytic constants of the uninhibited and inhibited steps respectively, 
KM and Ki are the constants for the first (uninhibitory) and second (inhibitory) αKG 
association events respectively, nH is the Hill coefficient (fixed at 1), x is the second Hill 
coefficient (fixed at 2) that takes into account the cooperativity of the inhibitory event: 
                                             𝑣/𝐸 =    !!"#!  !!  ×  ( !
!/!!!)
!  !   !!
!!
[!]!!
  !  ( ! !/!!!)
                      Equation 4.3 
The apparent KM from this fit is 52 ± 39 µM while Ki is 21 ± 9 µM. Fitting of the data 
points in the uninhibited region of the plot using the Michaelis-Menten equation (inset) 
gave an apparent KM value of 9 ± 1 µM. The reactions were performed at 37°C in 50 mM 
HEPES pH 7.02 containing 50 µM FeSO4, 2 mM ascorbate, 900 µM HIF-1α/CTAD,  
0.5 µM enzyme for WT and Y102F, 1 µM enzyme for K107A, 20 µM enzyme for 
Y102A, and 0-1000 µM αKG.  
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4.5.2.3 Intrinsic fluorescence quenching (or Trp quenching) assays to determine the 
binding affinity of HIF-1α/CTAD to (Co+αKG)FIH-1 
  
 
Figure 4.13 Binding of HIF-1α/CTAD to (Co+αKG)FIH-1 by monitoring the intrinsic 
protein fluorescence quenching at 330 nm. The fitted curves using the modified Hill 
equation (equation 3.1) gave KD values of 91 ± 5 µM for wild type, 204 ± 8 µM for 
Y102F, and greater than 500 µM for both Y102A and K107A. CoCl2 was used to replace 
Fe(II) in the active site. FIH-1 (2 µM) was equilibrated at RT (~25°C) with 25 µM CoCl2 
and 500 µM αKG in 50 mM HEPES pH 7.0 for about 3 mins and then titrated with  
HIF-1α/CTAD. The experiment was at least done in duplicate. The inset figure shows a 
sample of the raw fluorescence emission spectra generated. The arrow shows the trend of 





	   130	  
4.5.2.4 Binding of αKG to wild type versus Tyr102àAla FIH-1 
 
 
Figure 4.14 Binding of αKG to (Co)FIH-1 by monitoring the intrinsic protein 
fluorescence quenching at 330 nm. The fitted curves using the modified Hill equation 
(equation 3.1) gave a KD value of 35 ± 2 µM for wild type and 22 ± 2 µM for Y102A. 
CoCl2 was used to replace Fe(II) in the active site. FIH-1 (0.5 µM) was equilibrated at RT 
(~25°C) with 25 µM CoCl2 in 50 mM HEPES pH 7.0 for about 3 mins and then titrated 
with αKG. The experiment was done in triplicate. The inset figure shows a sample of the 
raw fluorescence emission spectra generated. The arrow shows the trend of decreasing 




Figure 4.15 Binding of αKG to (Fe)FIH-1 by monitoring the change in absorbance at 
λmax of 490-500 nm. The fitted curves using the modified Hill equation (equation 3.1) 
gave a KD value of 32 ± 9 µM for wild type and 25 ± 10 µM for Y102A. FIH-1 (200 µM) 
was anaerobically equilibrated inside the glovebox at RT (~25°C) with 198 µM FeSO4 in 
50 mM HEPES pH 7.0 for about 3 mins and then titrated with αKG. The experiment was 
at least done in duplicate. The inset figure shows a sample of the unsmoothed absorbance 
spectra generated. The arrow shows the trend of increasing magnitude of absorbance with 
increasing amounts of αKG. 
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4.5.2.5 Cu-EPR spectroscopy of wild type versus Tyr102àAla FIH-1 at low and high 
αKG 
 
Figure 4.16 Cu-EPR spectra of wild type and Tyr102àAla (Y102A) FIH-1 at low and 
high αKG levels. FIH-1 (275 µM) was equilibrated at RT (~25°C) with 250 µM CuSO4 
and 300 or 900 µM αKG in 50 mM HEPES pH 7.0 for about 5 mins and then transferred 
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4.5.2.6 Global HDX-MS of wild type versus Tyr102àAla FIH-1 at low and high αKG 
 
Figure 4.17 Global deuterium uptake plots showing the effect of low and high αKG on 
the backbone amide solvent accessibility of wild type versus Tyr102àAla FIH-1. The 
relative deuterium uptake (D) was calculated using the equation below[44]: 
𝐃 =    (𝒎𝒐𝒃𝒔  !  𝒎𝟎)
(𝒎𝟏𝟎𝟎!  𝒎𝟎)
                              Equation 4.4 
 The data were fitted to a tri-exponential equation (equation 4.5) (see Table 4.10A below 
for the summary of the fitted parameters). H/D exchange was initiated by diluting 
samples in 10 mM ammonium acetate buffer pD 7.4 to give a final concentration of  
20 µM FIH-1, 50 µM MnSO4 and 500 µM (high) αKG. Samples were quenched at 
various time points upon injection into the C4 column equilibrated with 0.1% formic acid 
at ~0°C and then analyzed using ESI/TOF mass spectrometry.  
 
Table 4.9A Comparison of the fitted parameters y0 (total exchangers), A (slow 
exchangers), B (medium exchangers), and C (fast exchangers) generated upon non-linear 
regression analysis of the global HDX data of wild type versus Tyr102àAla FIH-1 using 
equation 4.5.  
 
 Apo FIH-1a, b (Mn)FIH-1a, b Apo Y102Aa, b (Mn)Y102Aa, b 
y0 186 ± 1 199 ± 5 192 ± 2 200 ± 3 
Aslow 47 ± 2 60 ± 8 47 ± 3 52 ± 5 
Bmedium 55 ± 3 50 ± 11 51 ± 5 56 ± 8 
Cfast 84 ± 3 89 ± 10 94 ± 4 92 ± 7 
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Table 4.9B Comparison of the fitted parameters for wild type versus Tyr102àAla FIH-1 
at low and high αKG.  
 
aThe corresponding average rate constants were fixed accordingly during the fitting:  
k1 (0.05 min-1), k2 (1 min-1), and k3  (20 min-1)[45]. The initial parameters obtained were 
relative values; the number of exchangeable amides reported above was calculated by 
multiplying the relative values by N (N = 324). 
bErrors are associated with the derivation of the parameters using equation 4.5 where y0 is 
the actual number of exchangeable amide protons at a given condition (%D multiplied by 
N where N is the theoretical number of exchangeable amide protons; N = total amino 
acid residues – Pro residues – 1 for the N-terminus; for FIH-1, N = 324), A, B, and C 
correspond to the slow, medium and fast exchangers with assigned average rate constants 
k1 (0.05 min-1), k2 (1 min-1), and k3 (20 min-1) respectively: 
 









   
 (Mn+αKG)FIH-1a, b (Mn+αKG)Y102Aa, b 
High αKG Low αKG High αKG Low αKG 
y0 157 ± 2 167 ± 1 160 ± 2 173 ± 1 
Aslow 55 ± 4 51 ± 2 59 ± 3 53 ± 2 
Bmedium 51 ± 6 50 ± 3 49 ± 5 45 ± 4 
Cfast 51 ± 6 66 ± 2 52 ± 5 75 ± 4 
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4.5.2.7 Binding affinity of HIF-1α/CTAD to Tyr102àAla FIH-1 at low and high αKG 
  
Figure 4.18 Binding of HIF-1α/CTAD to (Co+αKG)Y102A at low and high αKG by 
monitoring the intrinsic protein fluorescence quenching at 330 nm. The fitted curves 
using the modified Hill equation (equation 3.1) gave KD values of 132 ± 6 µM at low  
(50 µM) αKG and greater than 500 µM at high (500 µM) αKG. CoCl2 was used to 
replace Fe(II) in the active site. FIH-1 (2 µM) was equilibrated at RT (~25°C) with  
25 µM CoCl2 in 50 mM HEPES pH 7.0 for about 3 mins and then titrated with 6.1 mM 
HIF-1α/CTAD. The experiment was at least done in duplicate. The inset figure shows a 
sample of the raw fluorescence emission spectra generated. The arrow shows the trend of 
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4.5.2.8 UV-vis spectrosocopy of wildtype FIH-1 in the presence of cofactors and 
substrate 
 
Figure 4.19 UV-vis spectra of wildtype FIH-1 (300 µM) in 50 mM HEPES pH 7.0 which 
was anaerobically equilibrated inside the glovebox at RT (~25°C) with one or two or all 
of the following components for at least 5 mins: 280 µM FeSO4, 600 µM αKG, 300 µM 
HIF-1α/CTAD. 
 
4.5.2.9 Autohydroxylation of wildtype FIH-1 and Tyr102àPhe as monitored by UV-vis 
spectroscopy 
  
Figure 4.20 Autohydroxylation spectra for wild type and the loop variant Tyr102àPhe. 
The arrow indicates the increase in the absorption signal of the chromophore with a λmax 
at 583 nm and 580 nm respectively. The spectra were obtained over a period of several 
hours after air exposure at RT (~23°C) of the anaerobically prepared samples (230 µM 
enzyme, 225 µM FeSO4, 1 mM αKG) in 50 mM HEPES pH 7.0. 
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4.5.2.10 Proposed solvent channel of FIH-1 in the absence and presence of substrate 
                 
Figure 4.21 Configuration of the proposed solvent channel residues (grey spheres) in the 
absence and presence of substrate (orange spheres). Tyr102 residue was highlighted in 
cyan (behind and to the left of Tyr103 residue) while the red sphere is the iron center. 
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